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Aluminium is an element of increasing clinical 
importance. It not only has uses as a medicinal substance 
but also in recent years it has been shown to be the 
cause of considerable toxicity, particularly in the 
setting of chronic renal failure. Diseases that have 
been shown to be associated with aluminium, or in which 
it has been implicated, include dialysis dementia, renal 
osteodystrophy and Alzheimer's disease. 
This thesis has studied aspects of the interaction 
between aluminium and the kidney. The work has addressed 
two major issues. 
Firstly, a study is 
technique was used to 
tubular site for Al in 
excreted in the distal 
described where Malvin's stop-flow 
determine any excretory/absorptive 
the pig kidney. Al was found to be 
nephron of the pig kidney. 
Secondly, the toxic effects of 
pig kidney cell line LLC-PKl 
attempt to elucidate some of 
action. 
Al in vitro on the DNA of 
were investigated, in an 
the mechanisms of toxic 
DNA synthesis was measured using 
3 H-TdR incorporation. 
Over increases of both time (9-72 h) and Al concentration 
(0.01-8.0 mM), 3 H-TdR incorporation was diminished. 
Effects were evident at concentrations as low as 0.05 mM 
Al. 
The production of DNA strand breaks was assessed by the 
increase in size of cell nucleoids (ie DNA in supercoiled 
form). Nucleoid size was analyzed in a Epics 753 
Fluorescence Activated Cell Sorter interfaced with an 
MDADSII data acquisition and analysis system. After 90 
min incubation with Al (over the concentration range 
0.001-32 mM), an increase in nucleoid size was noted at 
concentrations above 0.05 mM. 
The data demonstrate that Al exerts an effect on kidney 
cells in vitro which is expressed as diminished DNA 
synthesis and production of DNA strand breaks. These 
effects on DNA may have important long-term implications 
on various disease states associated with Al toxicity. 
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PREFACE 
This thesis deals with aluminium excretion by the distal 
tubule of the pig kidney and the toxic effects of the 
element on cellular DNA. 
The dissertation consists of three major parts: 
The first part broadly reviews the literature regarding 
aluminium toxicology. The material from this section 
formed the basis of a publication which appeared in 
Medical Toxicology (now called Drug Safety, published by 
Adis Press) entitled "Monteagudo FSE, Cassidy MJD, Folb 
PI. Recent developments in aluminium toxicology. Medical 
Toxicology 1989; 4:1-16". 
The second part deals with the excretion of aluminium by 
the kidney. The tubular handling of this process has 
previously been difficult to elucidate due to the 
unavailability of aluminium isotopes (which although they 
exist are extremely short lived). The technique of stop-
flow analysis was used to determine the site of aluminium 
excretion or absorption from the pig kidney tubule. 
Aluminium excretion in the distal tubule of the pig 
kidney was demonstrated, a previously unknown finding. 
The substance of this work was published in Nephron 
(Publishers S.Karger AG, Basel) in an article entitled 
2 
"Monteagudo FSE, Isaacson LC, Wilson G, Hickman R, Folb 
PI. Aluminium excretion by the distal tubule of the pig 
kidney. Nephron 1988; 49:245-250". 
The third part deals with the toxic effects of aluminium 
on DNA from pig kidney cells in in vitro culture. Using 
3 H-TdR incorporation aluminium was shown to decrease DNA 
synthesis. Aluminium also caused DNA strand breaks as 
evidenced by increased nucleoid size on flow cytometry 
measurement. This work, which adds new information to the 
site and mechanism of toxic action of this element, was 
presented in part at 
Pharmacology held 
the XIth International Congress of 
in Amsterdam 1990, and has been 
recently submitted for publication. 
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SECTION A 




Aluminium is an element of increasing clinical importance 
(Alfrey 1981, Krueger 1984). It not only has uses as a 
medicinal substance but also in recent years it has been 
be the cause of considerable toxicity, 
in the setting of chronic renal failure. 
shown to 
particularly 
Diseases that have been shown to be associated with 
aluminium, or in which it has been implicated, include 
dialysis dementia, renal osteodystrophy and Alzheimer's 
disease. Aluminium also has toxicological effects on red 
blood cells, parathyroid hormone and chromosomes. 
Aluminium is poorly absorbed from the gastrointestinal 
tract. Ions that are absorbed are cleared from the body 
mostly via the kidney. Toxicity usually occurs only when 
the body's physiological mechanisms are in some way 
undermined. The two common situations where this is found 
are when aluminium enters the body via a parenteral route 
(thus by-passing the gastrointestinal tract), and when 
renal function is impaired (thus reducing excretion). 
The latter mechanism is particularly important when 
combined with the excessive increase in aluminium 
ingestion that occurs following the use of 
aluminium-containing phosphate binders. 
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1. PHYSIOLOGY OF ALUMINIUM 
Normal dietary ingestion of aluminium is approximately 
3-5 mg/day, of which only about 15 µg is absorbed through 
the wall of the gastrointestinal tract. In humans, this 
small amount is usually excreted through the kidneys, 
maintaining the total body burden at approximately 30 mg 
(Alfrey 1984). Absorption of aluminium from the 
gastrointestinal tract has been demonstrated in humans, 
as well as in animal models (Ihle & Becker 1985; Kaehny 
et al. 1977b; Ott 1985; Recker et al. 1977; Eastwood et 
al. 1990). 
Once absorbed, aluminium is bound extensively to protein, 
predominantly transferrin (Rahman 1984). Consequently, 
only about 4% of plasma aluminium is filtered at the 
glomerulus (Henry et al. 1984). Evidence exists that 
aluminium may be further excreted by the distal nephron, 
near the sodium and calcium reabsorption sites 
(Monteagudo et al. 1988). Biliary excretion of aluminium 
has been described, and impaired hepatic function may 
contribute to aluminium toxicity (Williams et al. 1986). 
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2. SOURCES OF ALUMINIUM CONTAMINATION 
2.1. Contamination of water used in dialysis 
Although a link has been established between dialysis 
encephalopathy, renal bone disease and plasma aluminium 
concentrations, there was initially little idea of the 
source of aluminium. Ward et al. (1978) showed a strong 
association between dialysis bone disease and aluminium 
levels in the tap water used in dialysis units in the 
United Kingdom. Subsequently, further epidemiological 
studies in Europe showed that dialysis dementia was 
confined to certain geographical areas. It occurred more 
frequently if the dialysis water was untreated or 
softened, it was related to the water aluminium content, 
and it was often associated with osteodystrophy 
complicated by fractures (Wing et al. 1980). Kaehny et 
al. (1977a) showed that significant amounts of aluminium 
may be transferred from dialysis fluid to the plasma 
during haemodialysis. Since most aluminium is then bound 
to a nondialyzable plasma constituent, this precludes 
transfer in the reverse direction. These findings have 
been confirmed in other studies (Fuchs et al. 1984; 
Kovalchik et al. 
peritoneal dialysate 
(Cannata et al. 1983). 
1978). Aluminium contamination of 
at source has been described 
Using reverse osmosis and other 
22 
techniques the concentration of aluminium in the 
dialysate can currently be reduced to very low levels. 
2.2. Medicines containing aluminium 
Aluminium-containing antacids (such as aluminium 
hydroxide) are often used in the treatment of peptic 
ulcer disease and dyspepsia. Sucralfate, also used in 
the treatment of peptic ulcer disease, is an aluminium 
polymer which acts as a barrier-type protecting agent. 
Patients with chronic renal failure are unable to excrete 
phosphate normally and as 
develop hyperphosphataemia. 
a result they frequently 
This is a major cause of 
secondary hyperparathyroidism which leads to 
Briker 
renal 
osteodystrophy (Slatopolsky and 1973). 
Aluminium-containing phosphate binding gels are used in 




al. 1984) . 
diminish its absorption 
The binding gel adsorbs 
phosphorus through a chemical reaction to form an 
insoluble aluminium phosphate complex. In this way 
hyperphosphataemia is reduced and its adverse metabolic 
effects may be prevented or ameliorated. However, the use 
of aluminium-containing phosphate binding gels currently 
appears to be the major cause of aluminium toxicity in 
patients with chronic renal failure. 
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The gastrointestinal tract presents a relative barrier to 
ingested aluminium. It was not until the late 1970's that 
Kaehny et al. (1977b) showed that aluminium was absorbed 
in measurable quantities from the gastrointestinal tract 
of healthy volunteers. Subsequently, Andreoli et al. 
(1984) reported that aluminium intoxication developed in 
3 infants with azotemia who had been treated with 
aluminium-containing binding gels but were not dialysed. 
These infants had both severe osteomalacia and raised 
serum aluminium concentrations, thus confirming the 
absorption of aluminium from the gastrointestinal tract. 
2.3. Contamination of total parenteral nutrition (TPN) 
solutions 
Patients receiving long term total parenteral nutrition 
have been shown to develop bone disease, as well as a 
number of other complications (Folb 1985). Klein et al. 
(1982) demonstrated that such patients had elevated 
aluminium levels in bone, urine and plasma. This finding 
pointed to the casein used in the total parenteral 
nutrition being contaminated with aluminium, and it was 
found that aluminium levels fell when amino acids were 
substituted for casein. 
This was corroborated by Ott et al. (1983) who found that 
patients receiving casein in a total parenteral nutrition 
24 
solution had stainable aluminium on the surface of 
mineralised bone in a pattern similar to that found in 
dialysis osteomalacia. The same pattern was not found in 
patients receiving parenteral nutrition with amino acids 
as their nitrogen source. 
The American Food and Drug Administration (FDA) has 
considered imposing limits on the aluminium content of 
parenteral drug products (less than 100 µg/day). The FDA 
considers three groups of patients to be at particular 
risk, viz patients with renal failure, patients receiving 
long-term parenteral nutrition, and premature infants 
(WHO Advisory Notice 1990). 
2.4. Contamination of human serum albumin 
Plasmapheresis (plasma exchange) is a clinical procedure 
in which plasma is 
electrolytes and 
harmful substances 
exchanged for a solution 
human serum albumin. In 
in the plasma, such 




Recent work has demonstrated that in the process of its 
purification albumin may become heavily contaminated with 
aluminium. This was first described by Milliner et al. 
(1985), who showed that plasma and urine aluminium rose 
in a patient after plasma exchange. 
aluminium loading was due to 
25 
They found that this 
contamination of the 
albumin, probably during manufacture (Loeliger & de Wolff 
1985). This was subsequently confirmed in 4 other 
patients (Monteagudo et al. 1987). 
Plasmapheresis has been used in the past in an attempt to 
reduce the aluminium loading in patients with chronic 
renal failure (Elliot et al. 1978b). Although the body 
burden was apparently reduced, no long term benefit from 
this procedure was observed. This technique is unlikely 
to be of value, and is not recommended for the treatment 
of aluminium toxicity. 
A recent case report described a marked rise in plasma 
aluminium in a woman receiving human serum albumin for 
hypoalbuminaemia during continuous ambulatory peritoneal 
dialysis (Maher et al. 1986). The plasma aluminium 
level fell on discontinuation of the albumin. This 
problem is likely to continue to manifest itself in other 
situations where albumin is used, although the clinical 
significance has been questioned (Fell et al. 1986). 
2.5. Contamination of fluids used in infants 
Sedman et al. (1985) recently reported raised plasma, 
urinary and bone aluminium concentrations in premature 
infants compared with controls, and postulated that this 
group is at special risk because of the likelihood of 
26 
parenteral exposure and poor renal clearance. Many of 
the intravenous solutions investigated by these workers 
(in particular potassium phosphate, sodium phosphate, 
calcium gluconate and serum albumin) were found to be 
heavily contaminated with aluminium. The same findings 
were not confirmed, however, in a group of full term 
infants, emphasising the possible role of impaired renal 
function in premature neonates (Puntis et al. 1986). 
Freundlich et al. (1985) reported the findings of raised 
brain aluminium in postmortem specimens from two neonates 
with uraemia. Fluids to which these patients were exposed 
were analysed and found to contain negligible amounts of 
aluminium. However, the infant milk formula used 
( 'Similac PM 60/40') had an elevated aluminium 
concentration and was thought to be the most likely 
source of contamination. 
Concern has also been expressed about 
aluminium-containing injected vaccines in 
1986). 
the use of 
infants (Lione 
2.6. Contamination from environmental and 
sources 
Aluminium has been implicated 
(incoordination, intention 
in neurological 




defects) found in aluminium smelter workers (Longstreth 
27 
et al. 1985) . In addition, workers in aluminium 
smelters may have a greater incidence of bladder 
carcinoma than the general population (Theriault et al. 
1984), but no other risk of mutagenicity has been 
demonstrated in humans. No reports on the teratogenicity 
of aluminium are available. 
Atmospheric pollution in terms of sulphuric and nitric 
acid (so-called acid rain) has increased the leaching of 
aluminium from the soil. This has resulted in the 
elevation of aluminium concentration in the surface and 
ground water, where it has been shown to accumulate in 
the food chain (Cronan & Schofield 1979; Cronan et al. 
1978, 1986; Nordstrom & Ball 1986). Indeed, aluminium is 
an important participant in the 
acids in the soil (Johnson 1979). 
way the effect of acid rain on 
neutralisation of strong 
Thus, in an insidious 
aluminium solubility in 
the soil and the subsequent leaching of the element into 
nearby bodies of water may have important ecological 
consequences. Other writers have expressed concern 
about the use of aluminium cooking pots (Levick 1980), 
and about the levels of aluminium in various beverages 
such as tea (Coriat & Gillard 1986; Koch et al. 1988). 
3. MEASUREMENT OF ALUMINIUM 
The most popular and accurate method of aluminium 
measurement is by graphite furnace atomic absorption 
28 
spectroscopy (D'Haese et al. 1985; Parkinson et al. 
1982). Measurements by this technique give values in the 
parts per billion (ppb) range and are often expressed as 
µg/L or µmol/L. Normal human plasma aluminium values are 
generally accepted to be less than 10 µg/L, although 
values ranging from 2,1 to 42 µg/L have been described. 
Major problems in the assay technique at this level of 
sensitivity include that of contamination 
environment, in particular by metals (e.g. 
by the 
from 
needles) , glassware (e.g. laboratory containers), 
analytical reagents (including water) and airborne dust 
(Frech et al. 1982). Controversies still exist about 
the accuracy of aluminium assays in biological samples, 
particularly in serum (Adan et al. 1985; Berlyne & Adler 
1985; Burnatowska-Hledin 
Schutyser 1984). 
& Mayor 1985; Cornelis & 
Other methods of detecting aluminium have included 
/ 
histochemical techniques that stain the element (Pearse 
1972) and neutron activation analysis (Turkstra et al. 
1978). 
No stable radioactive isotopes of aluminium exist, and as 
a result no tracer studies using isotopes have been 
possible. This has inhibited aluminium research 
considerably, as a number of current investigative 
techniques are dependent on the existence of isotopes. 
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4. EXPERIMENTAL STUDIES 
4.1. Experimental studies in animals 
One of the earliest animal studies involving aluminium 
was conducted by Berlyne and co-workers (1972). They 
demonstrated a syndrome associated with periorbital 
bleeding, lethargy, anorexia and death due to aluminium 
loading in uraemic and non-uraemic rats, with the former 
being more seriously affected. Plasma and tissue 
concentrations of aluminium were found to be elevated. 
This experiment demonstrated the important effect of 
renal excretion on aluminium clearance by the body and 
the resultant toxicity in uraemic animals. 
Henry et al. (1984) administered 1 mg/kg of aluminium 
intravenously to dogs, and measured various parameters. 
The plasma half-life of the element was calculated to be 
276 + 51.8 minutes, and the volume of distribution 1.30 + 
0.17 liters or 5.90 + 0.30% of body weight. 10 to 21% of 
administered aluminium was found to be excreted in the 
urine over 150 min. The renal contribution to plasma 
clearance of aluminium correlated with the glomerular 
filtration rate (GFR). The 
aluminium (0.27 + 0.17 L/h) 
aluminium clearance (0.12 + 
total plasma clearance of 
was greater than the renal 
0.02 L/h), 
the widely held view that aluminium is 
thus confirming 
mainly, but not 
entirely, excreted renally. The difference between total 
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plasma clearance and renal clearance may be accounted for 
by the distribution of the aluminium into other body 
compartments such as bone, liver and brain. 
Henry et al. 
protein-bound. 
(1984) confirmed that aluminium is largely 
When measuring plasma concentrations, 
both protein-bound and free aluminium are measured. 
However, since proteins are normally not filtered by the 
glomeruli, the aluminium appearing in the urine 
presumably derives from the free fraction in the plasma, 
provided none is secreted or absorbed. In an effort to 
quantify the free aluminium fraction in plasma, Henry et 
al. (1984) examined the ultrafilterable fraction of 
aluminium in vivo (during a haemodialysis procedure in a 
dog) and found it to be 3.9%. They also looked at in 
vitro ultrafiltration by centrifuging plasma through a 
membrane and found the diffusable fraction to be 2.5%. 
Although these figures suggest that only a small fraction 
is filtered by the glomerulus, no data 
true glomerular filtered fraction. Henry 
exist to show the 
et al. (1984) 
measured total plasma levels of aluminium, and therefore 
the renal clearance of aluminium as measured by them does 
not have the same meaning as the "usual" renal clearance. 
A study of the renal excretion of aluminium in the rat 
using micropuncture techniques (Burnatowska-Hledin et al. 
1985) confirmed previous work (Henry et al. 1984) 
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showing that less than 8.4% of plasma aluminium is 
ultrafilterable. 
4.2. Human studies 
Recker et al. (1977) demonstrated that aluminium may be 
absorbed in considerable amounts if administered orally. 
They gave a group of 
orally and monitored 
aluminium before and 
6 volunteers aluminium carbonate 
the urinary concentrations of 
after the loading. The daily 
urinary aluminium excretion in the two control days was 
found to be 85.8 ~ 64.9 µg while during the 4 days of 
aluminium loading the daily urine Al ranged from non-
detectable to 1147 µg with an average steady-state 
urinary aluminium excretion of 495µg/d. 
Other available data are from clinical work and refer to 
aluminium measurements in the setting of a particular 
medical problem. Kaehny et al. (1977a) described two 
groups of patients with chronic renal failure, one 
dialysed with high-aluminium dialysate, the other 
dialysed with low-aluminium dialysate. They found that 
the low aluminium group excreted 9 + 9 µg/d and the high 
aluminium group 48 + 19 µg/d in the urine. The 
high-aluminium group were then dialysed for a period of 2 
months with low-aluminium-dialysate and their urinary 
excretion fell to 19 + 9 µg/day. 
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In their observation of inadvertent aluminium 
administration during a single plasma exchange, Milliner 
et al. (1985) found that aluminium concentrations in the 
urine increased. The levels were highest on the first 
day and fell over the following two days. It is of 
interest that although serum aluminium concentrations 
returned to baseline within 24 hours of the exchange, 
urinary aluminium levels remained elevated for a further 
48 hours, implying sequestration and subsequent 
mobilisation of aluminium from other body compartments. 
5. PATHOPHYSIOLOGY 
5.1. Aluminium, bone disease and the parathyroid gland 
Osteitis fibrosa cystica is a virtually universal 
accompaniment of chronic renal failure; osteomalacia is 
less common (Ellis & Peart 1973). The incidence of 
osteomalacia in patients prior to dialysis has varied 
according to the diagnostic criteria used, from 33% in 
Newcastle (Mora Palma et al. 1983) to 78% in Kentucky 
(Malluche et al. 1976). However, a severe form of 
fracturing osteodystrophy which histologically was due to 
osteomalacia was a major problem in certain dialysis 
units during the 1960s and 1970s (Pierides et al. 1980). 
Ionic aluminium readily crosses a dialysis membrane, and 
a patient undergoing haemodialysis is exposed to between 
300 to 400 litres of water each week across this 
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membrane. Dialysis units with a water supply that was 
high in aluminium 
(Parkinson 1979). 
experienced the greatest 
The incidence of this 
problems 
form of 
osteomalacia was clearly related to the duration of 
dialysis and was causally related to aluminium. 
The incidence of aluminium-related bone disease and the 
risk factors associated with its development since the 
advent of water treatment are difficult to determine. 
Malluche (1987) found stainable aluminium in 49% of 150 
unselected dialysis patients at his institution. In 
addition, 5% of predialysis patients with a glomerular 
filtration rate of between 10 and 15 ml/min had stainable 
bone aluminium. In a retrospective study from Montreal, 
chronic dialysis patients exposed to water with an 
aluminium content of less than 10 µg/L, 25% of patients 
undergoing bone biopsy had aluminium-related osteomalacia 
(Turner et al. 1988). 
Aluminium localisation in bone is demonstrable at the 
mineralisation front in trabecular bone using aurine 
stain. The rate of bone formation is inversely related to 
the amount of aluminium present (Ott et al. 1982), and 
can be evaluated by the incorporation of tetracycline 
into the mineralisation front. By using two time-spaced 
doses of oral tetracycline the rate of mineralisation can 
be quantitatively determined by microscopic examination 
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of the bone and measuring the distance between the two 
tetracycline labels. 
The mechanism by which aluminium causes osteomalacia is 
not fully established, and it may be multifactorial. 
Aluminium has been shown directly to inhibit osteoblast 
function (Dunstan et al. 1984), and deposits of 
aluminium within the mitochondria of osteoblasts in 
patients with aluminium bone disease can be detected on 
electron microscopy (Cournot-Witmer et al. 1986). The 
normal osteoblastic response to parathyroid hormone is 
reduced in the presence of aluminium. Furthermore, 
aluminium acts extracellularly at the mineralisation 
front, inhibiting the formation and aggregation of new 
bone crystals (Posner et al. 1986). 
The effect of aluminium on bone is mainly seen in 
trabecular bone. The difference in effect between 
trabecular and cortical bone may simply reflect the fact 
that the former is metabolically more active than the 
latter, or it may be due to local tissue factors. Certain 
patient groups appear more susceptible to aluminium 
deposition, for example the deposition of aluminium on 
bone surfaces in diabetic uraemic patients is enhanced 
compared with normals (Andress et al. 1987). 
The natural course of aluminium osteomalacia if the 
aluminium source is not removed is one of progressive 
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bone pain, fractures and deformity which are crippling 
(Ward et al. 1978). Bone pain may be an early feature, 
and back (on exercise often occurring first in the feet 
or standing), before becoming 
addition, a proximal myopathy 
more generalised. In 
occurs in the majority of 
patients, further aggravating the limitation of movement 
caused by bone pain. These clinical features are quite 
distinct from those found in bone disease associated with 
secondary hyperparathyroidism (osteitis fibrosa cystica) 
where bone pain is not a significant feature even in 
advanced cases. 
Laboratory and radiological features of the two 
conditions are also quite distinct. Patients with 
aluminium related bone disease typically have normal 
serum alkaline phosphatase, normal serum calcium, normal 
or high serum phosphate, and low circulating parathyroid 
hormone. Incorporation of calcium into bone in the 
presence of aluminium is impaired, and hypercalcaemia may 
readily occur in this setting with the administration of 
Vitamin D. Radiological hallmarks of the disease are 
osteopaenia, pathological fractures and Looser's zones 
although these features are usually only seen in advanced 
cases. In contrast, patients with osteitis fibrosa 
cystica characteristically have high serum alkaline 
phosphatase, low or normal serum calcium, high serum 
phosphate, high circulating parathyroid hormone, 
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radiological evidence of subperiosteal erosions, and a 
good response to Vitamin D (Massry 1986). 
Parathyroid hormone has been implicated in the 
pathogenesis of aluminium-related renal bone disease as 
well as in altering the distribution of aluminium in 
tissues (Alfrey 1985b; Mayor 1985). The role of 
parathyroid hormone and phosphate in bone disease is well 
known, and it may be that it is partly through these 
mechanisms that some of the effects of aluminium on bone 
are mediated (Kaye & Gagnon 1985). Although aluminium 
binds dietary phosphate due to its physicochemical 
properties, it is possible that it may exert additional, 
less well-defined effects on phosphate metabolism. 
Urinary phosphate has been shown to decrease after 
aluminium loading in both animal and human 





et al. (1984) showed that 150 minutes after a 
injection of aluminium the parathyroid hormone 
in dogs fell by 27 + 4%. They noted that although 
the calcium in the serum and the urine rose 15 minutes 
after injection this was unlikely to be a hormonal effect 
because of the rapidity of the response. Moreover, 
ionised calcium, which is thought to be the calcium 
fraction causing a parathyroid hormone response, did not 
increase. The serum phosphate rose slightly during the 
150 minutes, but this rise was significantly different 
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only at 30 minutes compared with baseline. For reasons 
that were not explained urinary phosphate concentrations 
were not studied. 
Mayor et al. (1977, 1980) studied rats that had been 
loaded with oral aluminium, and noted that parathyroid 
hormone increased the absorption of aluminium by the 
gastrointestinal tract. Levels of aluminium in various 
tissues also increased significantly. The authors 
confirmed these findings by withdrawing parathyroid 




levels. This effect might be influenced 
cholecalciferol (Burnatowska-Hledin et 
Cann et al. (1979) studied aluminium levels in 
parathyroid glands, thyroid and cervical muscle in 
healthy and hyperparathyroid human subjects and in rats. 
They found that in all these categories the level of 
aluminium in the parathyroid glands was significantly 
greater than in other tissues, and was linearly related 
to dietary aluminium intake. 
Morrissey et al. (1983) 
quantity of aluminium from 
found that by increasing the 
0.5 to 2.0 mmol/L in an in 
vitro parathyroid cell culture they inhibited the 
secretion of parathyroid hormone. This effect was 
reversible, as normal secretion returned on placing the 
38 
cells in an aluminium-free medium. 
techniques they demonstrated that 
was due to decreased secretion 
Using radiolabelling 
the inhibitory effect 
of parathyroid hormone 
from the cell rather than interference with biosynthesis 
within the cell. 
The inhibitory effect of aluminium on bone may in part be 
brought about by its effect on the parathyroid gland. 
Parathyroid hormone secretion is regulated by protein 
kinase C (Morrissey 1984), which in turn is dependent on 
calcium, phospholipids and diglyceride levels. Aluminium 
has been shown to reduce diglyceride levels in dispersed 
bovine parathyroid cells and thereby reduce parathyroid 
hormone secretion (Morrissey & Slatopolsky 1986). 
Parathyroidectomy in patients with chronic renal failure 
is associated with enhanced 
(Andress et al. 1985) . 
bone deposition of aluminium 
It has been shown that 
aluminium-induced osteomalacia may deteriorate after 
parathyroidectomy in some patients (Felsenfeld et al. 
1982). 
Parathyroid hormone has been shown to modulate toxicity 
of other metals such as cadmium (Washko & Cousins 1979) 
and lead (Six & Goyer 1970), in addition to aluminium. 
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5.2. Aluminium and the brain 
The first reported case of human aluminium intoxication 
presented with neurological manifestations, namely memory 
loss, tremor, jerking movements and impaired coordination 
(Spofforth 1921). Since then aluminium has been 
associated with several neurological syndromes. 
5.2.1. Alzheimer's disease 
Alzheimer's disease is a dementing illness that afflicts 
approximately 2 million Americans, and it has been 
estimated that at least 100 000 of them will die from the 
disease every year (Wurtman 1985). Various hypotheses 
about the aetiology of this disease exist, of which the 
aluminium theory is but one (Crapper et al. 1973, 1976; 
Delaney 1979; Foncin 1987; Perl & Brody 1980; Shore et 
al. 1980; Wascher & Cohn 1985; Yates 1980). The nuclei 
of brain cells containing neurofibrillary tangles (which 
are the distinctive histological feature of Alzheimer's 
disease) have been shown to have nuclei which are, in a 
high percentage of cases, positive for aluminium when 
studied by scanning electron microscopy and x-ray 
spectrometry (Perl & Brody 1980). Injection of aluminium 
into the brains of certain animals has induced the 
development of similar neurofibrillary tangles (Crapper 
et al. 1973). Aluminium has been shown to affect the 
blood-brain barrier by increasing its permeability, and 
altering membrane function (Banks & Kastin 1983; Banks & 
Kastin 1989). 
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A controversial epidemiological study 
districts in England and Wales showed 
of 88 county 
that the risk of 
Alzheimer's disease was 1.5 times higher in districts 
with an aluminium concentration in the drinking water 
greater than 0.11 mg/L than in districts with water 
aluminium levels smaller than 0.01 mg/L (Martyn et al. 
1989) . 
5.2.2. Dialysis encephalopathy 
It has been suggested that aluminium might play a role in 
the pathogenesis of the dialysis encephalopathy syndrome 
(Alfrey et al. 1976) and raised aluminium levels have 
been found in post-mortem brain specimens (McDermott et 
al. 1978). That aluminium is the cause of dialysis 
dementia is now beyond doubt (Alfrey 1985a, Arieff 1985). 
Non-specific symptoms 
including malaise, loss 




progression of stuttering 
precede the condition 
memory and concentration, 
clinical features are a 
to aphasia; twitching to 
myoclonus; 
dementia. 
and mild personality disorders to seizures and 
Typical electroencephalographic abnormalities 
generalised slowing of the normal rhythm with include 
bursts 
features 
of high voltage, slow frequency waves. These 
are characteristic, but not diagnostic, of 
dialysis dementia (Smith et al. 1978). 
41 
How aluminium exerts its toxicity on the brain in this 
condition is unclear. Using histological techniques 
aluminium has been shown to concentrate predominantly in 
the grey matter of the brain. This histological hallmark 
of toxicity in experimental animals is neurofibrillary 
tangles (Wisniewski et al. 1970), which are similar but 
not identical to 
(Crapper et al. 
dementia, however, 
those found in Alzheimer 1 s disease 
1973). In patients dying of dialysis 
the pathological changes in the brain 
are usually nonspecific and neurofibrillary tangles are 
rarely found (Bugiani et al. 1985). 
5.2.3 Other disorders 
In addition to Alzheimer's disease and dialysis dementia, 
aluminium has been associated with other neurological 
disorders such as amyotrophic lateral sclerosis and 







has also indicated that 
predispose to epileptic 
patients treated with seizures in renal transplant 
cyclosporin (Nordal et al. 1985). 
5.2.4 Biochemical considerations 
At the molecular level, aluminium may affect brain 
biochemistry by various mechanisms. Aluminium has been 
shown to affect synaptosomal membranes in vitro (Lai et 
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al. 1980), and to decrease synaptosomal uptake of 
glutamic acid, gamma-aminobutyric acid (GABA) and glycine 
(Wong et al. 1981). It is also possible that aluminium 
interferes with brain cytochrome oxidase activity. 
Animal studies have shown that after aluminium ingestion 
the levels of adenosine triphosphate (ATP) in the blood 
fall, and the levels of adenosine diphosphate (ADP) and 
adenosine monophosphate (AMP) rise (Ondreicka et al. 
1966). These changes were accompanied by impaired 
incorporation of RNA and DNA into the tissues (Ondreicka 
et al. 1966). Within 6 hours of intrathecal aluminium 
injection the element can be shown histochemically to be 
preferentially attached to nuclear chromatin in cerebral 
cortical cells (De Boni et al. 1974). In animal studies 
aluminium-induced neurofibrillary tangles in the central 
nervous system have been associated with an increase in 
brain aluminium and a decrease in the activity of choline 
acetyl transferase and acetyl cholinesterase (Yates et 
al. 1980). More recently it has been found (Altmann et 
al. 1987) that aluminium may inhibit dihydropteridine 
reductase (DHPR) activity in erythrocytes. 
is essential for 
neurotransmitter, 
the normal synthesis of 




erythrocytes. Although it has not been measured in the 
brains of dialysis patients it may be that erythrocyte 
levels of DHPR reflect brain levels. 
43 
5.3. Aluminium and anaemia 
Aluminium rapidly distributes between plasma and red 
blood cells, with only small quantitative differences 
existing between the two compartments (van der Voet & de 
Wolff 1985). 
It was demonstrated as long ago as 1929 that aluminium 
toxicity in animals results in an anaemia similar to that 
found in lead poisoning (Siebert & Wells 1929). In 
humans the observation was made in 1978 (Elliot & 
MacDougall 1978a) that some dialysis patients with 
encephalopathy and some with aluminium related bone 
disease develops a severe hypochromic microcytic anaemia 
despite adequate iron treatment. O'Hare and Murnaghan 
(1982) demonstrated that there was an improvement in the 
anaemia of 15 chronic haemodialysis patients who were 
transferred from a high-aluminium to a low-aluminium 
water supply. This was confirmed by others (Touam et al. 
1983). Studies in humans thus far only provide 
circumstantial evidence that aluminium toxicity produces 
anaemia, but the evidence of animal studies is less 
equivocal (Berlyne et al. 1972). 
There are several mechanisms that may be implicated in 
the pathogenesis of the anaemia. Various metals, 
including aluminium, affect the activity of 
delta-aminolaevulinic acid (d-ALA) dehydratase (McGonigle 
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& Parsons 1985). However, clinical studies show a wide 
scatter in the activity of d-ALA hydratase which does not 
correlate with blood aluminium levels. Aluminium in 
blood is bound to transferrin (Rahman et al. 1984), and 
it is possible that by preventing loading or unloading of 
iron onto this molecule anaemia may be produced. 
Interference with iron transport may also occur in the 
bone marrow. Aluminium is deposited in macrophages within 
the marrow and this may interfere with the macrophages' 
role of digesting redundant erythrocytes and recycling 
iron. The effects of aluminium on DNA (Karlik et al. 
1986) and calmodulin (Siegel & Haug 1983) in vitro 
suggest other hypotheses for the molecular basis of the 
anaemia. 
6. TREATMENT 
The management of aluminium toxicity can be classified 
into three major areas: the identification of the source 
of the aluminium, the removal of the aluminium from that 
source, and the use of desferrioxamine. 
6.1. Identification of aluminium sources 
This has been dealt with in a previous section, which 
described some of the currently known sources of 
aluminium. It will be important in the future to 
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maintain a high degree of suspicion in detecting new 
sources of aluminium loading. 
6.2. Removal of aluminium 
6.2.1. Removal from water 
Patients with renal 
been identified as 
failure undergoing haemodialysis have 
a group at risk from long term 
aluminium accumulation, due to the contamination of the 
water used for dialysis. The concentration of aluminium 
in municipal water supplies varies from place to place, 
and this explains the clustering of dialysis dementia and 
bone disease in certain renal units (Barratt & Lawrence 
1975; Hudson et al. 1979; Wing et al. 1980). This 
variation in aluminium content may be due to the fact 
that in many areas municipal water is treated by alum 
precipitation. Reports from different centres throughout 
the world have since confirmed the beneficial effects of 
removing aluminium from water used for dialysis (Hodge et 
al. 1981; Kerr et al. 1986; Milne et al. 1982; Platts & 
Anastassiades 1981). 
There is no "safe" level of water contamination with 
aluminium, although it has been suggested that at 
dialysate aluminium concentrations greater than 14 µg/L 
aluminium transfer will occur (Hodge et al. 1981). One 
epidemiological study showed that few cases of fracturing 
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osteodystrophy occurred in centres where the local tap 
water contained less than 50 µg/L (Parkinson et al. 
1979). It has, however, been shown that aluminium 
accumulation can occur in a few long-term haemodialysis 
patients treated with a dialysate containing less than 30 
µg/L of the element (although these patients were also 
prescribed aluminium-containing phosphate binding gels) 
(Kerr et al. 1986). 
The two usual methods for water purification in dialysis 
units are deionisation and reverse osmosis. Deionisers 
are used for the removal of dissolved inorganic ions; 
they contain cationic resins which exchange hydrogen ions 
for dissolved cations and anionic resins which exchange 
hydroxyl groups for dissolved anions. 
Potential problems with deioniser use are bacterial 
contamination and an acidic effluent as the exchange 
capacity of the deioniser is saturated. The latter can 
lead to leaching of copper from pipes and copper toxicity 
(Manzler & Schreiner 1970). It may also inactivate 
heparin, leading to clotting of dialysers (Schwarzbeck et 
al. 1977). 
Reverse osmosis is superior to deionisation in the 
removal of aluminium. In addition to removing dissolved 
inorganic ions it removes dissolved organic substances, 
particulate matter, bacteria and pyrogens. The principle 
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of the technique is based on molecular sieving and ionic 
exclusion. Pressure is applied across a membrane (of 
which there are several types eg. cellulose). When the 
applied pressure is greater than the osmotic pressure 
solvent will move from the more concentrated side of the 
membrane to the other. 
6.2.2 Removal from phosphate binders 
Aluminium-containing phosphate binding gels are often 
important therapy for patients with chronic renal failure 
and associated high serum phosphate levels. They are 
used to bind dietary phosphate and thus decrease its 
absorption. However, it has been shown by Kaehny et al. 
(1977b) that aluminium is absorbed from 
aluminium-containing phosphate binding gels in the 
gastrointestinal tract. Consequently, nephrologists have 
become cautious about their use. An important practical 
point is that the binding gels should only be given at 
the time of main meals, to provide optimal phosphate 
binding. Phosphate control appears to be better in those 
patients who have normal gastric acid secretion (Cassidy 
et al. 1988) and the capacity of aluminium-containing 
phosphate binding gels to bind phosphate has been shown 





al. 1986) and in 
has been demonstrated to be an 
binder both in adults (Slatopolsky et 
children (Andreoli et al. 1987) with 
chronic renal failure. 
magnesium-containing 
Other centres have been using 
antacids in 
magnesium-free dialysate in similar 
aluminium exposure (Wheeler et al. 
have, however, found this to 
combination with 
attempts to minimise 
1986). Some workers 
be ineffective and 
associated with magnesium toxicity (Jennings et al. 
1986). Other than calcium carbonate, no satisfactory 
non-toxic phosphate binders are currently available. 
More recently, 
investigated as 
natural polymeric anions have been 
phosphate binders, with 
results (Schneider et al. 1983). 
encouraging 
Effective 
non-aluminium containing phosphate binders which are also 
non-toxic would be a major development in nephrology. 











Desferrioxamine is principally used in practice 
of 
to 
chelate iron. It also chelates various other metal ions, 
and its affinity for aluminium is high (Swartz 1985). 
The aluminium-desferrioxamine complex has a molecular 
weight of approximately 587 daltons (L~ung et al. 1985) 
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and is dialysable. As it is not well absorbed orally 
desferrioxamine must be administered parenterally for 
systemic effect. It is predominantly excreted by the 
kidney, with more than 70% of an administered dose 
appearing in the urine of patients with normal renal 
function. Ackrill and colleagues were the first to 
report its use intravenously 
aluminium overload in chronic 
(Ackrill et al. 1980). 
in the treatment of 
haemodialysis patients 
There have been several subsequent reports on the 
effectiveness of desferrioxamine in reversing the 
manifestations of aluminium toxicity in dialysis dementia 
(Ackrill et al. 1986; Milne et al. 1983; Pogglitsch et 
al. 1981), aluminium related anaemia (Swartz et al. 
1985), and aluminium related osteodystrophy (Ackrill et 
al. 1982; Ihle et al. 1982; Malluche et al. 1984). 
Desferrioxamine can be given intravenously, 
subcutaneously or intraperitoneally (for those patients 
on chronic ambulatory peritoneal dialysis). The best 
mode of administration and the optimum dose have not yet 
been established. Smaller doses given more frequently (1 
gram three times weekly) (Ihle et al. 1982) have been 
shown to be as effective as larger doses in removing 
aluminium. Malluche et al. (1984) used a dose of 
28.Smg/kg 3 times weekly infused during the first two 
hours of dialysis. With this dose no complications were 
seen during a 10-month follow-up period. Infusion of 
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desferrioxamine at a dose of between 15 and 20mg/kg body 
weight once weekly, during the last hour of dialysis is 
also practised. 
rather than at 
Administration at the end 
the beginning minimises 
of dialysis 
loss of 
desferrioxamine in the dialysate. 
Data on whether the type of dialysis membrane used 
affects the aluminium-desferrioxamine complex clearance 
are conflicting. While some authors have demonstrated 
that high flux membranes (e.g. polyacrilonitrile) have 
been associated with high clearances compared with 
standard cuprophane membranes (Chang & Barre 1983), 
others have not shown this association 
1984; Malberti et al. 1986; Muirhead et 
would, however, be expected in 
(Banal et al. 
al. 1986). It 
view of the 
aluminium-desferrioxamine complex, that clearance would 
be more efficient with high flux dialysis membranes. 
The necessary duration of treatment with desferrioxamine 
is also unclear. A striking clinical improvement is seen 
in patients with proximal myopathy and bone pain, often 
within 1 month of starting therapy (Malluche et al. 
1984). Interestingly, this clinical improvement is seen 
before a large amount of aluminium can have been removed. 
It would seem that treatment is required for 6 to 9 
months in many cases. 
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A single infusion of desferrioxamine results in peak 
serum levels of Al 24 to 40 hours after administration, 
and this 
aluminium 




determine the body 





(1984) found that 12 patients with aluminium accumulation 
in bone experienced a rise in serum aluminium following a 
single desferrioxamine infusion, but elevations were also 
seen in some of 10 patients without bone aluminium 
accumulation. The investigators concluded that the test 
cannot be used specifically to diagnose the accumulation 
of aluminium in bone, and suggested that the rise in 
serum aluminium seen 
accumulation may have 
from other tissues. 
in patients without bone 
been due to release of the metal 
Another explanation may be contamination of the 
desferrioxamine itself with aluminium. This has been 
demonstrated recently in three batches of commercially 
available desferrioxamine (Wagner et al. 1985). The 
desferrioxamine test is not absolutely specific or 
sensitive and a reasonable guideline would be to consider 
an increment in the serum aluminium of 150 µg/L or more 
as indicating a positive test (de Broe et al. 1988). 
Iron deficiency due to depletion of total body stores may 
occur during desferrioxamine treatment, although this is 
rare. However, serum ferritin levels fall significantly 
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with treatment (Swartz et al. 1985) . Although other 
trace metals such as manganese, copper, tin and zinc bind 
to desferrioxamine, deficiency states have not been 
reported on treatment. Bone copper has been shown to be 
depleted during treatment with desferrioxamine but a true 
deficiency state has not been reported (Hewitt et al. 
1986). 
Other more serious side effects of desferrioxamine 
treatment include anaphylactic reactions and visual 
disturbances (Davies et al. 1983; Simon et al. 1983). In 
addition, there have now been several reports of serious 
and fatal cases of opportunistic infections such as 
mucormycosis (Eiser et al. 1987; Windus et al. 1987) and 
systemic yersiniosis (Boyce et al. 1985; Robins-Browne & 
Prpic 1983) in patients receiving desferrioxamine. Many 
of these side effects are probably dose related. 
Desferrioxamine scavenges free radicals and modifies 
neutrophil and 
Gutteridge 1985), 
macrophage function (Halliwell & 
which may affect host immunity. It has 
been shown that the virulence of yersinia is increased by 
the presence of desferrioxamine (Robins-Browne & Prpic 
1983). Whether or not it can be utilised by the 
Mucorales fungi to affect their growth in a similar 
fashion is not known. In 
inhibit the fungistatic 
(Holzberg & Artis 1983). 
addition, desferrioxamine may 
properties of transferrin 
It is currently unclear which· 
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of these mechanisms, if any, are 
pathogenesis 
there is 
of this opportunistic 
a sub-population of 





specifically at risk. Occasionally, transient worsening 
of dialysis dementia has been reported, in association 
with the short-lived rise in plasma aluminium levels that 
may occur after desferrioxamine administration (Ackrill 
et al. 1980). 
7. CONCLUSION 
There has been an explosion of knowledge with regard to 
aluminium in the last decade. Aluminium has been shown 
to be involved in pathological processes involving 
primarily brain and bone, particularly in patients with 
renal failure. In addition, the numerous ways a person 
can be exposed to aluminium (mainly iatrogenic) have 
become better known. However, many of the public health 
concerns about the toxicity of this substance in the ill, 








It is known that the excretion and absorption of various 
ions takes place at defined sites along renal tubules. 
Although it is known that the kidney as a whole excretes 
Al, the mechanisms by which this takes place are largely 
unknown. 
In this section a study is described where Malvin's 
stop-flow technique was used to determine any 
excretory/absorptive tubular site for Al. 




1.1 Renal handling of aluminium 
Al is excreted primarily by the kidneys (Alfrey et al. 
1976). Various kinetic studies have been performed on Al 
renal excretion (Henry et al. 1984; Hohr et al. 1989). 
Very few studies have addressed the issue of the renal 
tubular handling of this element. Where along the 
tubule, if at all, excretion or absorption takes place is 
not definitively established. 
The reasons for this lack of knowledge may relate to the 
very small quantities of sample volume produced by 
techniques such as micropuncture and isolated perfused 
tubules (Burg 1982). No stable isotope of aluminium 
exists which might make the assay of the element in 
nanolitre volumes feasible. Using Graphite Furnace 
Atomic Absorption Spectroscopy (GFAAS) the volume of 
sample required is in the 
et al. 1985; Parkinson 
order of microlitres 
et al. 1982). The 
(D'Haese 
use of 
micropuncture or perfused isolated tubule techniques 
producing nanolitre volumes is therefore not possible in 
the direct study of aluminium transport in the renal 
tubule. 
Burnatowska-Hledin et al. (1985) noted the problem of the 
nanolitre quantities produced by micropuncture 
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techniques, stating in their paper "However, a direct 
determination of aluminum concentration in tubular fluid 
was not feasible because of the sample size required for 
analysis with presently available methods". Their data 
indicated that at elevated plasma aluminium levels less 
than 8.4% of plasma aluminium was ultra-filterable 
suggesting extensive plasma protein binding. Increased 
excretion of aluminium in response to volume expansion 
was noted but not to furosemide. The authors thus 
suggested the proximal tubule as a major site of 
aluminium reabsorption. This observation was made by 
inference only, as the authors themselves acknowledged in 
their paper (Burnatowska-Hledin et al. 1985). 
Review of the literature has not produced evidence of 
other work dealing with the tubular handling of Al. 
1.2 Introduction to stop-flow experiments 
1.2.1 Alternative techniques 
Renal tubular transport mechanisms are routinely studied 
using kidney micropuncture or perfusion of isolated 
tubule segments (Burnatowska-Hledin et al. 1985; Stokes 
1982; Burg et al. 1966; Burg 1982). A major drawback of 
both these techniques is that they produce nanolitre 
volumes of tubular fluid for analysis. 
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The only technique allowing the direct study of renal 
tubular handling of Al (because it produces substantial 
for GFAAS assay) is the stop-flow 
Malvin et al. (1958a; 1958b). 
assay volumes suitable 
technique described by 
This technique permits localization of sites of maximal 
absorption or excretion of various substances along the 
length of the nephron. 
1.2.2. Concept of stop-flow 
Malvin et al. explained the concept of their technique in 
a publication (1958a). The following is a quotation from 
the article describing the concept: 
"The method depends upon the concentration pattern 
derived from urine samples caught serially from a 
catheter following a brief period of ureteral 
occlusion. If a dog is infused with a high load of 
osmotic diuretic, such as mannitol, the urine to 
plasma concentration ratios (U/P) for most 
substances approach 1 . 0. If now the ureteral 
catheter is occluded, filtration at the glomeruli 
will stop when the tubular pressure becomes equal to 
the net filtration pressure. The urine in the 
tubules which had been relatively unchanged from 
that of glomerular filtrate will now be exposed to 
the action of the various nephron segments for as 
long as the ureteral occlusion lasts. Previous 
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administration of the osmotic diuretic provides a 
watery menstruum against which electrolytes may be 
reabsorbed. The various substances will now be 
reabsorbed or secreted more completely, and new U/P 
ratios developed which will differ from the control 
U/P ratio. Also, the concentration of any substance 
will vary along the nephron depending upon how the 
individual segments handle that substance. 
Creatinine concentrations might be 
along the entire nephron only as a 
expected to vary 
result of water 
movement, secreted substances would show an increase 
in concentration in the nephron areas which secrete 
that substance, while the concentration of 




for the concentration 
ample time has 
patterns to 
develop during stopped flow the ureteral occlusion 
is released. Rapid serial urine samples are taken 
from the new flow. The concentration pattern is 
caught in these 
the polyethylene 
samples collected rapid fire from 
ureteral catheter after the brief 
occlusion is released." 
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FIGURE 1: Diagram demonstrating the concept 
of stop-flow. The sodium (Na), calcium (Ca) and 
phosphate (Pt) sites of absorption against their 
concentration gradients are marked. 
1.2.3. Rationale for the interupted stop-flow technique 
The interrupted stop-flow technique was described by 
Murdaugh and Robinson (1960). It is a modification of 
Malvin's stop-flow technique and consists of two 
consecutive ureteral occlusions separated by a brief 
period during which the first ureteral occlusion is 
temporarily relieved and the released fluid discarded. 
Subsequent to the second occlusion the urine samples are 
serially collected in the usual stop-flow fashion. 
By using this technique the proximal tubular fluid 
modified during the first period of stop flow will move 
downstream into the distal nephron during the period of 
temporary release following the first occlusion. This 
facilitates the demonstration of distal excretion of 
those solutes which had been reduced to low 
concentrations proximally. 
1.2.4. Critique of the stop flow method 
The crucial advantage of the stop flow method is that it 
produces large sample volumes which allow for the assay 
of aluminium by GFAAS. 
Drawbacks of the technique include the fact that the 
samples collected are not coming from a single tubule but 
collectively from all the tubules in the kidney. These 
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tubules are obviously of varying lengths, thus when we 
discuss a "tubule" in the stop-flow context it is a 
hypothetical structure. The localization of any 
reabsorption or excretion site to a limited precise area 
of the tubule is therefore inexact. In addition, 
glomerular filtration does not cease during stopped flow, 
and on release of stopped flow the proximal tubular fluid 
concentrations are necessarily further modified as the 
fluid passes through the distal nephron prior to 
collection. 
Thus, the technique does not have the precision that 
micropuncture or perfusion of isolated tubular segments 
allows. Nonetheless, numerous relevant experiments have 
been conducted using this particular technique (Samiy et 
al. 1960; Murdaugh and Robinson 1960; Swanson and Hakim 
1962). 
1.3 The animal model 
The animal model chosen for this experiment was the pig. 
There were two major reasons for its use. Firstly, the 
Landrace x White is an animal model which is in common 
use at the University of Cape Town Medical School. 
Expertise exists on procedures in that animal at the 
Department of Surgery's Animal Laboratory. 
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The second reason for using the pig as an animal model is 
because of the similarities between pig and human renal 
physiology. In particular, nephron type, maximum urine 
concentration, and maximum urine/plasma osmolal ratios 
have been shown to be similar in both (and both are quite 
different from the dog) (Nielsen et al. 1986). 
Munsick et al. (1958) showed the pig to be a good model 
for renal studies. They also found that the clearance of 
endogenous creatinine was consistently lower in pigs than 
the clearance of inulin. The reason for this was 
unexplained. Subsequently Suarez et al. (1968) confirmed 
the similarities between the pig kidney and the human 
kidney but also noted that the manner in which the pig 
cleared creatinine is still unresolved. 
1.4. Introduction to aluminium assay 
1.4.1. General 
The two major areas of concern with regard to Al assay 
are avoidance of contamination by the element, and the 
technique of using graphite furnace atomic absorption 
spectroscopy (GFAAS). 
There is wide variability in the literature regarding 
"normal" values for human serum and urine Al. In a 
survey of data published from 1974 to 1984 the range of 
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serum Al values was between 2.1 µg/L and 42 µg/L; the 
range of urine Al values was between 4.7 µg/L and 1700 
µg/L (Cornelis & Schutyser 1984). The issue arises as to 
whether this large range is due to a wide variability in 
the "normal" range or whether it is due to differences 
and problems in analytical technique including care taken 
to prevent contamination (Berlyne 1985; Adan 1985; 
Burnatowska-Hledin and Mayor 1985). 
1.4.2. Prevention of aluminium contamination 
Contamination of Al is a major factor in the accuracy of 
assaying the element at low concentrations (Cornelis & 
Schutyser 1984; Frech 1982; D'Haese 1985; Burnatowska 
-Hledin and Mayor 1985). 
1. 4. 3 Dust control 
A study conducted by Cornelis & Schutyser (1984) showed 
that a major source of Al contamination was from the air 
in the environment. 
Figures quoted for Al contamination from air fall-out 
were 179 µg/m 2 /d outdoors, and 8.2 µg/m 2 /d in an 
analytical laboratory. There was a 9-fold decrease in 
the Al content of a clean-air laboratory as compared to 
the usual analytical environment (Cornelis & Schutyser 
1984) . 
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Frech et al. (1982) took blood samples from 43 normal 
individuals in a hospital, taking the usual precautions, 
and reported a mean blood Al level of 7.5 (SD~ 6.41) 
µg/L. In a separate study, using the same technique they 
took blood samples from 11 different volunteers in a 
dust-free atmosphere and found the mean blood Al to be 
1.6 (SD ~ 1.29) µg/L. Analyzing this discrepancy they 
concluded that contamination during sampling could have 
been a factor in the higher normal values found in the 
samples collected in the hospital. 
1.4.4. Preparation of containers 
The containers used may cause analytical problems either 
by increasing the Al content of the sample due to Al 
contamination of the vessel, or alternatively by 
decreasing the Al content by promoting adsorption of the 
element onto the wall of the container. These sources of 
/ 
analytical error are dependent both on the nature of the 
sample and the container (Cornelis & Schutyser 1984). 
In order to decrease Al contamination of containers or 
other laboratory equipment these should be washed 
thoroughly, and stored for at least 12 h in a 10% nitric 
acid solution and then rinsed for several hours in 
Al-free water. 
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Moreover, the containers are composed of ~aterials which 
may contain Al. Laboratory glassware may contain 100 µg 
Al/g, whereas high pressure polyethylene contains between 
0.01 and 0.1 µg Al/g (Cornelis & Schutyser 1984). In 
general, plastics contain less Al than glass. 
It is also possible for Al to adsorb to the walls of 
containers, particularly if stored for long periods of 
time. Refrigeration of the samples (rather than 
freezing) may prevent losses of Al in this way (Cornelis 
& Schutyser 1984). 
1.4.5. Solutions 
Water can be a major source of contamination in the 
of equipment, containers, and making up cleaning 
solutions. Water Al content varies in different areas 
(Ward et al. 1978). The only way to ensure that the 
water source is Al-free is to use double-deionised or 
reverse-osmosis water prepared by an appropriate 
filtration system. Only this Al-free water should be 
used in all aspects of Al measurement, including washing 
of containers and making up of solutions. 
It has been well established that tap water and distilled 
water may contain appreciable amounts of Al (Ward et al. 
1978). The use of double-deionised or reverse osmosis 
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water is necessary to produce water with Al levels of <10 
µg/L. 
Reagents used should be of a high degree of purity, with 
a minimum Al content. 
1.4.6. Analytical techniques 
Problems may be experienced in the measuring of urine or 
serum Al by GFAAS because of matrix effects ie the 
effects of substances other than Al in the sample being 
analysed. As a result samples are often "pre-treated" to 
facilitate their measurement. 
effective method appears to be 
with water, although Triton-X 
been used (Frech et al. 1982; 
The simplest and most 
by diluting the sample 
and other techniques have 
D'Haese et al. 1985). 
The preparation of a suitable standard is also important. 
It is important that the standards have the same 
constituents, other than Al, as the sample being studied: 
ie that sample-based standards be used. 
A number of methods exist for measuring Al in various 
fluids and tissues (Burnatowska-Hledin and Mayor 1985; 
Berlyne 1985). These include neutron activation, X-ray 
microanalysis, inductively coupled plasma (ICP), atomic 
emission spectrophotometry, atomic 





GFAAS is the method of choice in many dialysis centres 
measuring Al in serum, urine and dialysis waters {D'Haese 
et al. 1985; Gorsky and Dietz 1978; Frech et al. 1982). 
Various instrument settings and heating programs exist, 
depending on local experience with the particular machine 
used, the sample pre-treatment performed and the sample 
to be analysed. 
An Autosampler was found to be an essential part of the 
equipment for a number of reasons. Firstly, it allowed 
accurate pipetting from 5 µl to 50 µl, in 1 µl 
increments. Secondly, the pipetting is done accurately 
by the pipetting arm so that the sample pipetted is 
deposited at exactly the same spot in the graphite tube, 
which increases accuracy. 
1.4.7. Choice of units 
The concentration of a substance may be expressed as µg/L 
or as mmol/L. The S.I. system allows the expression of 
concentrations in both these formats (Reynolds 1989). 
the low concentrations of Al usually Considering 
discussed in this section µg/L has been used. The 
conversion factor for Al is 
3.706 x 10-s . µg/L = mmol/L. 
69 
2. MATERIALS AND METHODS 
2.1. Aluminium assay 
2.1.1. Prevention of aluminium contamination 
As reviewed in the previous section, the main 
contaminants of Al arise from atmospheric dust, glass, 
metals and reagents. 
Dust control 
All containers and tubes once cleaned were kept stoppered 
to prevent dust contamination. Whenever possible the 
tubes were opened in a laminar flow hood. If 
circumstances did not permit the use of a laminar flow 
hood, the tubes were left open for the shortest possible 
time. Solutions were made up in the laminar flow hood. 
Once containers had been cleaned and required drying, 
this was done by air drying them in the laminar flow 
hood. 
Preparation of containers 
Only plastic containers and 







required to make up stock solutions. All containers and 
equipment used were cleaned {after washing) by immersing 
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overnight in 10% nitric acid (AnalaR, BDH, Ltd) and then 
rinsing for a few hours in Al-free water. The containers 
were then dried in a laminar flow hood. Periodically, 
containers were tested to ensure that they were Al free. 
The nitric acid and water used as cleaning solutions were 
kept in plastic buckets with tight fitting lids. These 
solutions were changed every few weeks. 
Solutions 
Tap water and distilled water may contain considerable 
amounts of Al. Only Al-free water was used throughout 
all the experimental stages of this research (eg washing 
of equipment, making up solutions, dilution of samples). 
Al-free water, repeatedly tested to contain 
non-detectable levels of Al, was obtained from two 
sources: 
a) A Milli-Q Water filtration system 
b) Commercially as "Sterile Water for Irrigation" ( Cat 
No AFB 7114, Sabax Ltd, Johannesburg). 
All solutions were made up using Al-free water in a 
laminar flow hood. The Maintalyte Solution (Cat No AFB 
2774, Sabax Ltd, Johannesburg; containing electrolytes 
and 10% dextrose in water) and 0.9% saline solution (Cat 
No AFB 1324, Sabax Ltd, Johannesburg) were also assayed 
and found to have non detectable levels of Al. 
71 
High purity grade reagents were used and were checked 
periodically to ensure that they had not become 
contaminated with Al. 
Miscellaneous 
Surgical gloves were not used during the collection or 
analysis of the samples as the powder that is used to 
coat them contains Al. Samples were stored at 4°C until 
assayed. 
Plastic, disposable, acid-washed pipette tips were used 
to measure the fluid aliquots. The plastic auto-sampler 
cups for use in the GFAAS were cleaned as described 
above, and stored in a closed plastic container until 
ready for use. 
The Al standard used was ''Aluminium nitrate Standard 
Solution for AAS" (SpectrosoL, Cat No 14031 4S, BDH 
Chemicals Ltd, Poole, UK.). This solution contained 1 mg 
Al/ml or 1 000 ppm or had a concentration of 37.1 mmol/L 
of Al. This solution was then appropriately diluted to 
serve as standards for the GFAAS determinations. The 
standard solutions were kept in plastic vials and made up 
fresh every 2-3 weeks. 
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2 . 1 . 2 . Graphite furnace atomic absorption spectroscopy 
(GFAAS) technique 
Equipment 
Perkin-Elmer 5000 Atomic Absorption Spectrometer 
Perkin-Elmer HGA 500 Programmer 
Perkin-Elmer AS-40 AutoSampler 
Perkin-Elmer 56 Recorder 
Pyrolytically-coated graphite furnace tubes 
Sample preparation 
The sample volume in all the urine assays was 20 µl. 
Urine samples were diluted 
where the level of Al was 
was increased appropriately. 
Setting-up of GFAAS 
The GFAAS technique was 
1:2 with water. In cases 
too high the dilution factor 
carried out according to 
methodology recommended by Prof M Orren, Associate 
Analytical Professor and Head of the Department of 
Chemistry at the University of Cape Town. 
The samples were assayed in an argon gas flow. The 
injection port-hole was cleaned to remove any residue 






been used for Al estimations) 
a new tube was used it was 
"conditioned" prior to use by firing it at gradually 
increasing temperatures until 2700°c was reached. 
The settings on the spectrometer were: aluminium hollow 
cathode lamp wave length 309.3nm, slit 0.7nm, lamp 9mA. 
A furnace temperature of 2400°c was then selected on the 
Programmer. While depressing the "Manual Temperature" 
button the calibrating dial in front of the furnace was 
turned until the red and green lights were both on 
together. The locking lever was then used to fix the 
settings. 
Once the spectrometer was set up 
adjusted to provide the optimum 
as above, the lamp was 
reading. The furnace 
alignment was also adjusted using the screws provided, so 
that the furnace was directly in the path of the light 
beam. 
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Calibration of the GFAAS was done prior to each run. The 
calibration was performed on sample based standards, 
using a sample from the batch to be assayed and spiking 
the sample with known quantities of aluminium. The 
Autosampler was used in all instances. 
VALIDATION OF ASSAY 
CALIBRATION CURVE 
The instrument produced a linear relationship between 
GFAAS units and Al concentration from 0-100 µg/L, the 
equation of the calibration curve being y=0.00413x x (SE 
~ 0.00015) with a correlation coefficient of r=0.9987 
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FIGURE 2: Regression lfne of alumlntum concentratton 
versus graphite furnace atomtc absorption units. 
Repeatability 
six blank samples spiked with 200 µg/L Al showed a 
coefficient of variation of 1.94%. 
Sensitivity 
For purposes of this study Al concentrations less than 10 
µg/L were considered to be "non-detectable". 
Effect of different concentrations 
phosphate on the Al assay 
of calcium and 
To determine the magnitude of interference (if any) from 
Ca or Pi, known quantities of Al were spiked with 
increasing concentrations of Ca or Pi. 
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Calcium 




























For details of Calcette assay please see Section 2.2.5. 
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Phosphate 









2.2. Other assays 









According to the S.I. system the concentration of a 
substance may be expressed as mg/dL or mmol/L (Reynolds 
1989). The conversion factor for calcium is y mg/dL = 
y/4 mmol/L. The conversion factor for phosphate is y 
mg/dL = y/3.096 mmol/L. 
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2.2.2. Inorganic phosphate (Pi) assay 
The assay used was based on the method described by Chen 
et al. (Chen et al. 1956). 
Equipment and materials 
A Beckman Model 35 spectrophotometer (Beckman Instruments 
Inc., Irvin, California) was used. 
REAGENT c was made up as follows: 
1 vol 6N sulphuric acid 
2 vol distilled water 
1 vol 2.5% ammonium heptamolybdate 
1 vol 10% ascorbate 
Standards 
Urine aqueous standards were used containing 3.33 mg 
Pi/dL and 10 mg Pi/dL and used as appropriate. 
Serum standards containing 3.6 mg Pi/dL were obtained 
commercially (Versatol, General Diagnostics, Morris 
Plains, New Jersey, USA). 
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Method 
Initial urine Pi preparation 
Twenty microlitres urine (on occasion with low 
absorbances 40 µl urine was used) and 100 µl of 10% 
trichloroacetic acid were mixed with 1 ml Reagent Cina 
test-tube. The resultant solution was processed as 
described below. Standard phosphate solutions of 3.33 mg 
Pi/dL and 10 mg Pi/dL were prepared. 
Initial serum Pi preparation 
Forty microlitres serum (20 µl serum was found to give 
absorbances that were too low) and 200 µl of 10% 
trichloroacetic acid were mixed together in a test-tube. 
After standing for 10 minutes the solution was 
centrifuged and 100 µl of the supernatant was added to 1 
ml Reagent c. 
The resulting solution was processed as described below. 
Final processing of urine and serum samples 
After the urine and serum samples had been prepared as 
described above they were treated similarly. The samples 
were incubated in a water-bath at 37°c for 90 minutes. 
The samples were then placed in the spectrophotometer and 
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read at an absorbance of 700 nm. Each specimen was 
assayed in duplicate. By using the appropriate standards 
the absolute values of Pi were obtained. 
2.2.3. Creatinine assay 
Equipment 
Glucose, Urea, Creatinine Analyzer Model 919 using 
Auto-sampler Model 461 (Instrumentation Laboratory, Inc, 
Lexington, Massachusetts, USA). 
Method 
The auto-analyzer was used following the manufacturers' 
instructions. The machine required 240 µl per assay. 
Where necessary the sample was diluted with water. 
2 . 2 . 4 . Inulin assay 
The inulin assay was based on the method of Young and 
Raisz (1952). 
Equipment and materials 
A Beckman Model 35 spectrophotometer (Beckman Instruments 
Inc., Irvin, California) was used. 
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Anthrone Reagent 
Two grams of anthrone was placed in a 500 ml volumetric 
flask and dissolved in 125 ml concentrated sulphuric 
acid. The volume was then adjusted to the mark with 
diluted sulphuric acid (2:1). This procedure was carried 
out in a water bath. 
Method 
Initial urine preparation 
The samples were prepared in duplicate. 
Ten µl of urine was mixed with 200 µl of water and 10 µl 
of 4N sodium hydroxide in a 
was heated for 20 minutes at 
test-tube, and the solution 
95°c in a heating block. 
The tubes were inverted to collect the condensed fluid. 
An amount of 50 µl was removed and placed in a clean 
glass tube. 
Standards of 12.5, 50, 100 and 200 mg/dL inulin were 
processed in the same way. 
Initial measurement in plasma 
The samples were prepared in duplicate. 
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An amount of 100 µl of serum was diluted with 0,980ml 
water in a test-tube. To this was added 75 µl of 10% 
zinc sulphate and 75 µl of 0,5N sodium hydroxide. 
Standards of 25, 50, 100, 200 and 400 mg/dL inulin were 
processed in the same way. 
After centrifugation 400 µl of supernatant was removed 
and 100 µl 4N sodium hydroxide was added. At the end of 
this period, 200 µl was removed and placed in a clean 
glass tube. 
Final processing of urine, serum samples and standards 
After the initial preparation of the urine and serum 
samples, the tubes were placed in an ice-water mixture, 
and 1 ml of the cold anthrone reagent was added. The 
tubes were agitated while in the ice-water to ensure 
; 
thorough mixing. They were then placed in a 75°c 
water-bath for 5 min after which they were cooled by re-
immersion in ice water. The samples were read in the 
spectrophotometer at 630 nm after waiting for at least 15 
minutes. 
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2.2.5. Calcium assay 
Equipment 
Calcette - Automatic Calcium Analyzer (Model No. 4008, 
Precision Systems 
Calcette measures 
Inc, Sudbury, Massachusetts). The 
total calcium by a fluorescence 
technique. Reagents and standards as supplied by the 
manufacturers. 
Method 
The "Calcette" Automatic Calcium Analyzer was used in 
accordance with instructions from the manufacturers. The 
procedure was the same for urine or serum. The machine 
required 80 µl per assay and the assays were all done in 
duplicate. The standard used was 10 mg/dL aqueous 
calcium as supplied by the manufacturer. Once the 
/ 
machine was calibrated, readings were obtained directly 
from the digital read-out. 
2.2.6. Sodium assay 
Equipment 
Sodium Flame Photometer Model 543 (Instrumentation 
Laboratory Inc., Lexington, Massachusetts, USA). 
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Method 
Samples were read directly from the Flame Photometer, 
after previous calibration. 
2.3. The experiment 
2.3.1. Setting up the animal model 
Landrace x Large White pigs were obtained from the 
University of Cape Town Animal House. Both male and 
female pigs were used, with a median weight of 24.5 kg 
(range:19 to 40 kg). They were maintained on a balanced 
diet, were in good health and had not been used in any 
experiment previously. 
experiment conducted. 
Fresh pigs were used for each 
They were fasted overnight prior to the day of the 
experiment to avoid anaesthetic complications. On that 
morning the experimental pig was transferred to the UCT 
Department of Surgery's Animal Theatre where the 
procedures took place. 
Once in the animal theatre the pigs were weighed and then 
anaesthetised using thiopentone sodium induction and a 
nitrous oxide/oxygen mixture (at a flow rate of 4 1/min 
and 2 1/min, respectively). Respiration was maintained 
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via an endotracheal tube using a volume cycled 
respirator. 
Once the pig was anaesthetised a plastic catheter was 
inserted into an external jugular vein for infusion and 
subsequent injections. Another plastic catheter was 
inserted into the external carotid artery, for collection 
of blood samples, and monitoring of blood pressure to 
note undue fluctuations. Temperature was not monitored. 
A mid-line laparotomy was then performed. A plastic 
catheter was inserted into the right ureter, with its tip 
sited in the renal pelvis. The catheter was then tied 
firmly in place; its free end passed through the 
laparotomy incision into a measuring cylinder. 
Urine from the left kidney collected in the bladder 
during the experiment, and in order to prevent bladder 
distension, pain and subsequent neurogenic stimuli, the 
bladder was drained by means of another catheter. The 
urine drained from the bladder was discarded and did not 
play a part in any of the results shown. The laparotomy 
wound was partly closed, with the abdominal contents 
covered with damp swabs in order to minimise fluid loss 
from evaporation. 
Once all the appropriate catheters had been inserted a 
solution containing 10% dextrose water was infused 
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intravenously at a rate sufficient to 
In Pigs I to VII the solution used 
available liquid Maintalyte (Sabax, 
produce a diuresis. 
was a commercially 
Ltd). In Pig VIII 
0.9% saline (Sabax, Ltd) to which dextrose had been added 
to achieve a final dextrose concentration of 10%, was 
used. 
2.3.2. The typical experiment 
Once the animal model had been set up as described above 
and there was a copious diuresis ensuing from the 
ureteric catheter the experiment was ready to begin. 
Experimental plan 
A total of eight pigs was used in these experiments. 
Pigs I and II were used to demonstrate endogenous 
secretion of Al, and also acted as controls. 
Pigs III and IV were used to determine a suitable dose 
range of Al to be used in subsequent experiments. 
Pigs V,VI,VII and VIII received 0.1 mg Al/kg b.w .. In 
these four pigs seven regular and four interrupted 
stop-flows were performed. The inulin clearances were 
determined in pig VIII. 
88 
Urine free-flow periods 
The urine free-flow periods are those during which urine 
flowed freely before and after the stop-flow experiments. 
During these periods blood and urine samples were 
collected. From these samples plasma and urine creatinine 
and occasionally inulin were assayed. These assays were 
used to determine the single kidney creatinine clearance. 
Stop-flow experiments 
Regular stop-flow 
After a variable number of free-flow measurements had 
been taken a stop-flow experiment was 
The ureteric catheter was clamped for 
then performed. 
five minutes and 
when the clamp was released the ensuing gush of urine was 
collected serially in 40 tared, labelled 1.5 ml Microfuge 
tubes. Each tube received about 0.5 to 1.0 ml of urine, 
and was promptly sealed to minimise Al contamination. 
The volume of urine in each tube was determined by the 
subsequent weighing of the tubes and equating a gram with 
a millilitre of urine. 
Since it was found that each tube did not contain enough 
urine to enable all the assays to be done, the tubes were 
consecutively paired and the data presented as such. 
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Thus, every alternate tube was used for Al measurement; 
the remaining tubes were used for the sodium, phosphate, 
calcium and creatinine assays. The results are displayed 
as 20 data points, each representing the concentration in 
the tubes of the various substances at that point. 
Interrupted stop-flow 
Four interrupted stop-flows were conducted in Pigs V and 
VIII. In each case, the catheter was occluded for five 
minutes, the clamp then released allowing approximately 
10 ml of urine to escape, and the ureteric catheter then 
occluded for a further five minutes. 
After this second occlusion, stop-flow samples were 




During the course of the experiment in each pig a test 
substance was injected as a slow IV bolus. Only two 
solutions made up in sterile water, were injected 
aluminium chloride and hydrocnloric acid. Hydrochloric 
acid was chosen as the control substance, as it could 
suitably be matched to the pH of the Al and it also 
contained a chloride ion. 
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Pigs I and II received 0.037 ml/ kg b.w. 
hydrochloric acid solution. 
of the 
Pigs III and IV received 1.0 mg/kg b.w. and 0.5 mg/kg 
b.w. respectively of the aluminium chloride solution. 
Pigs V,VI,VII and VIII received 0.1 mg/kg b.w. 
aluminium chloride solution. 
of the 
2.3.3. Creatinine and inulin clearance studies 
These clearance studies were conducted in the usual 
fashion. A timed collection of urine was obtained, and 
by measuring the serum and urine creatinine (or inulin) 
the clearance was obtained. Important points with regard 
to the experiment were: 
1. The timed period was 5 minutes (measured with a 
digital stopwatch). 
2 . The urine was collected from the ureteric 
into a graduated measuring. cylinder. 





3. The blood sample was obtained from the arterial line 
via a three-way tap. The sample was then centrifuged 
and the serum stored. 
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4. The clearance values obtained apply to only one 
kidney, as the urine was collected from the single 
ureteric catheter. 
Using this information clearances were calculated as: 
CREATININE OR INULIN CLEARANCE= U.V ml/min 
p 
where 
U = urine cone of creatinine (µmol/L) or inulin (mg/dL) 
P = serum cone of creatinine (µmol/L) or inulin (mg/dL) 
V = urine volume passed in one minute (ml/min). 
3. RESULTS 
3.1. General 
Details of the experimental plan in each of the eight 
pigs are set out in the Appendix, including the timed 
sequence of events and the weight of each pig. The 
free-flow studies are designated numerically, 
stop-flows alphabetically. For greater clarity 
and the 
an (R) or 
(I) after the stop-flow denotes a regular or interrupted 
stop-flow respectively. For example, S-F.V.A(R) 
92 
designates a stop-flow in pig V, which was the first one 
conducted in that pig (ie A), and which was a regular 
stop-flow (ie R). 
The median weight of the pigs was 24.5 kg (range: 
kg) . 
19-40 
In the control pigs I and II, there were 18 free-flow 
studies and 4 stop-flows (all "regular"). In pigs III 
and IV, the pigs used to establish the dose range of Al, 
there were 17 free-flow studies and 6 stop-flows (all 
"regular") . In pigs V, VI, VII and VIII there were 34 
free-flow studies and 13 stop-flows (9 "regular" and 4 
"interrupted"). These last 13 stop-flows formed the basis 
of the final analysis. 
3.2. Urine free-flow studies 
/ 
3.2.1. Single kidney creatinine and inulin clearances 
In all eight pigs the single kidney creatinine clearance 
was found to be 25.2 ml/min (range: 16.3-34.7 ml/min), 
and in pig VIII where inulin clearances were also done, 
the inulin clearance was 34.0 ml/min (range: 29.5-37.6 
ml/min). The median ratio of creatinine to inulin 
clearance was 0.69 (range: 0.58-0.78). The median urine 
flow rate from a single kidney during the clearance 
collections was 4.7 ml/min (range: 3.0-9.0 ml/min). 
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The sodium and phosphate maximal reabsorption sites, are 
arbitrarily designated 0% and 100% of the intratubular 
volume respectively, and act as markers for tubule 
length. The median tubular urine volume (ie between sites 
0% and 100%) collected in the series of stop-flows was 
11.4 ml (range: 9.2-16.2 ml). 
In the eight pigs, the creatinine clearances were 
determined on 3 (range: 2-6) occasions prior to injection 
with Al or control, and on 5 (range: 
afterwards. 
3.3. Stop-flow studies 
3.3.1. Control experiments 
4-8) occasions 
Measurable quantities of aluminium were not detected in 
the urine, either before or during stop-flow. 
3.3.2. Dosage experiments 
The initial quantities (1 and 0.5 mg Al/kg b.w.) of 
aluminium used to determine the final dose to be 
administered were unnecessarily large in terms of what 
could be measured. Consequently, 0.1 mg Al/kg b.w. was 
arbitrarily chosen as the standard dose in the remaining 
animals. 
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3.3.3. Aluminium experiments 
The results from the stop-flow experiments in four pigs 
dosed with 0.1 mg Al/kg b.w. are presented. 
The fractional excretion of filtered creatinine along the 
length of a ,,tubule,, was calculated in those four stop-
flows in which inulin was measured concurrently. Peaks or 
troughs in creatinine along the length of the ,,tubule" 
were not detected. 
The pooled results for the aluminium excretion in the 
stop-flows are displayed 
flow experiment, the 
in Figure 3 (a). In each stop-
Al/creatinine ratio in each 
intratubular sample was expressed as a percentage of the 
peak Al/creatinine value found. The individual stop-flows 
demonstrated patterns of excretion and reabsorption 
similar to those illustrated in Figure 4a) and b) of s-
F.V.A(R). The sodium, phosphate, calcium and aluminium 
concentrations are represented as relative to that of 
creatinine concentration. Figure 4 (a) demonstrates the 
sites of maximal reabsorption of sodium phosphate and 
calcium. Figure 4 (b) demonstrates the creatinine and the 
aluminium/creatinine concentration along the tubule. In 
the series of experiments the median calcium/creatinine 
minimum was at site 14% (range: 11 to 27%) and the 
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FIGURE 4a: Graphs demonstrating the ratios 
of sodium/ creatinine, phosphate/ creatinine, 
and calcium/ creatinine during stop-flow. 
The free-flow urine values immediately prior 
to this experiment for sodium/creatinine, 
phosphate/ creatinine and calcium/ creatinine 
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FIGURE 4b: Graphs demonstrating the creatinine 
and the Al/creatinine ratios during stop-flow. 
Free-flow urine values immediately prior to this 
experiment for Al/ creatinine and creatinine were 
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FlGURE 5a: Graphs demonstrating the ratios 
of Na/ creatinine, phosphate/ creatinine and 
calcium/ creatinine during interrupted 
stop-flow. 
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FIGURE Sb: Graphs demonstrating the creatinine 
and the Al/creatinine ratios during interrupted 
stop-flow. 
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Four interrupted stop-flow experiments were conducted in 
two pigs. The pooled results (pooled in an analogous 
manner to Figure 3 (a)) for the aluminium excretion in 
the interrupted stop-flows are displayed in Figure 3 (b). 
The individual interrupted stop-flows demonstrated 
patterns of excretion and reabsorption similar to those 
illustrated in Figure 5 a) and b) of S-F.V.B(I). 
Interrupted stop-flow was done immediately after the 
regular stop-flow in Figure 4, on 
graphs in Figure 5 a) and b) 
the same animal. The 
demonstrate analogous 
features to those in Figure 4 a) and b), as set out in 
the above paragraph. 
The results of the interrupted stop-flow demonstrate that 
aluminium excretion continues in the second half of the 
experiment. This excretion causes a peak of aluminium to 
become evident in the previous proximal low that has been 
shifted to lie opposite the aluminium excretory site in 
the distal nephron. Moreover, distal to the 
aluminium/creatinine peak shown in the stop-flow no 
further aluminium reabsorption or excretion occurs. 
4. DISCUSSION 
4.1 Discussion of the Literature 
The kinetics of Al in humans and animals have been 
described. The kidney is known to be the major route of 
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excretion of the element. Despite this the way in which 
Al is handled by the kidney is still not clearly defined. 
It is known that the element is highly protein bound in 
plasma and that only about 3-5% is cleared in the urine. 
Previous to this current work it was not definitively 
known if the element was purely filtered by the 
glomerulus, or if reabsorption or secretion by the tubule 
takes place. 
Only one paper was found where an attempt was made to 
elucidate mechanisms of tubular handling of Al 
(Burnatowska-Hledin et al.1985). 
been described in Introductory 




inferred that Al was reabsorbed in the proximal tubule 
because the excretion of Al increased in response to 
volume expansion but not to furosemide. 
noted that a direct determination of 
technique was not possible. 
The authors 




above as background the concept of using the 
technique of Malvin et al. (1958a) was 
This technique has in most instances been 
superseded by micropuncture and isolated perfused tubule 
methodologies which are more precise. A critique of 
stop-flow methodology is found in the Introductory 
Section 1.2.4. Nonetheless, this technique has been used 
extensively and produced results which were found to be 
comparable to data produced by other methodologies. Its 
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advantage in this study is the fact that it produces 
sample volumes that are adequate for GFAAS. 
The interrupted stop-flow method was devised by Murdaugh 
and Robinson (1960) and is also described in the 
Introductory Section 1.2.3. The particular 
technique is that it allows detection 
value of this 
of possible 
secretion into the distal tubule of solutes with a low 
solute/creatinine ratio proximally. It increases the 
"signal/noise" ratio and so facilitates detection of 
possible ion exchange phenomena (eg sodium/hydrogen) 
which might otherwise be obscured by high concentrations. 
So for Al in particular, the distal Al/creatinine ratios 
can be seen to be still high after interrupted stop-flow 
despite the fact that the distal Al/creatinine ratio 
immediately after the release of the fluid after the 
preliminary stop-flow must have been low. 
The experimental animal chosen for this series of 
experiments was the 
has already been 
between the human 
pig. The reasoning for this 
noted (Section 1.3.) The 
and the pig kidney were 




Hohr et al. (1989) demonstrated in their isolated 
perfused rat kidney experiments that acutely administered 
Al did not affect general kidney functions, such as GFR, 
urine volume, the excretion of potassium and the fraction 
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reabsorption of sodium and glucose. This may be of 
significance in the stop-flow study suggesting that the 
acute administration of Al to the pigs (although a 
different species and dose range) would not interfere 
with their renal function. 
The developing of the GFAAS technique was a major part of 
this research. To start with the samples had to be kept 
free of significant Al contamination. In the Al range of 
<10 µg/L contamination is more difficult to control but 
this experiment only considered values above this. 
Nonetheless, scrupulous attention was given to potential 
sources of contamination, as described (Section 1.4) in 
order to increase the accuracy. This involved care in 
the solutions used, the containers and avoiding 
environmental dust. 
The GFAAS technique would appear to be the 11 gold 
standard 11 for measuring Al in the µg/L range. Various 
modifications of this technique have been described, but 
the one that was used was developed by Professor M. 
Orren of Analytical Chemistry, University of Cape Town 
(Personal communication). Sample based standards were 
used in order to minimize matrix (ie substances present 
in the sample other than Al) effects. The effects of 
phosphate and calcium on the assay were examined (Section 
2.1.2) and found not to be critical. 
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Various other assays were performed for phosphate, 
creatinine, inulin, calcium and sodium (Section 2.2). 
These methodologies are well described in the literature 
and were routine clinical laboratory assays in many 
cases. 
4.2 Discussion of experimental work 
4.2.1. Urine free-flow periods 
In order to establish the validity of creatinine as a 
marker of water reabsorption, inulin levels were 
determined concurrently in four stop-flows (2 regular and 
2 interrupted). The GFR calculated by the creatinine 
clearance was consistently lower than when calculated by 
the inulin clearance, as had been noted in previous work 
in pigs (Munsick et al. 1958). The reason for this 
difference is not established. Examining the fractional 
excretion of filtered creatinine at various points along 
the nephron, no peak or trough pattern for that substance 
could be found. Moreover, division of a solute 
concentration by that of creatinine did not alter the 
site of the trough for that solute (e.g. sodium or 
phosphate), as previously classically described (Malvin 
et al. 1958a). The inulin and creatinine graphs were 








same finding of an Al peak in the distal nephron. As 
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such, it was felt that creatinine could be used as a 
marker for water reabsorption (although not for GFR). 
4.2.2. Stop-flow 
The conc8ntration of many substances appears to rise 
along the 
compensate 
tubule due to water reabsorption. To 
the for this water reabsorption, 
concentrations of these substances were expressed as 
ratios relative to the creatinine concentration. A more 
exact index of excretion is the calculation of the 
fractional excretion of the filtered substance. However, 
for this calculation to be correct, the substance must be 
freely available for filtration through the glomerulus. 
This is not the case with Al which is extensively protein 
bound with only a small percentage existing in the free 
form in the plasma, thus making precise calculation of 
the fractional excretion impossible (Henry et al. 1984). 
In all the stop-flow experiments the relationship of Na, 
phosphate, and calcium maximal reabsorption sites 
(against their concentration gradient) was as described 
by previous workers, confirming the general validity of 
the technique (Malvin et al. 1958a). 
The median Al/creatinine peak occurred at site 12% 
(range:-27 to +31%) of intratubular length, near the site 
of maximal calcium and sodium reabsorption. The pooled 
107 
data for all the stop-flows 
This (together with the 
indicates Al excretion in 
range in the Al/creatinine 
relative inaccuracy of 
are displayed in Figure 3a. 
interrupted stop-flow data) 
the distal nephron. The wide 
peaks may be due to the 
the stop-flow technique. 
Moreover, since there are only about seven data points 
between sites O and 100%, the location of the site is 
relatively inaccurate. 
Significant reabsorption of Al against its concentration 
gradient at the proximal nephron is not likely as the 
Al/creatinine levels at that site are in the same range 
as those in the free-flow tubular fluid (points> 150%). 
Al excretion rather than secretion is noted, as an active 
mechanism for this process has not been demonstrated. The 
excretion of Al at the distal tubule could possibly be 
due to passive diffusion in a manner analogous to that 
postulated for Na in the collecting tubule (Stokes 1982). 
4.2.3. Interrupted stop-flow 
A typical interrupted stop-flow is demonstrated in Figure 
5. Pooled data for the interrupted stop-flows are 
displayed in Figure 3b. Values were generally higher 
than in the regular stop-flow because of the greater 
duration of the procedure. 
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The difference between the Al/creatinine graphs in the 
stop-flow and the interrupted 
as follows. During the first 
stop-flow an Al peak similar 
stop-flow can be explained 
5 min of the interrupted 
to that demonstrated in 
Figure 4 is likely to develop. By allowing some fraction 
of the intratubular fluid volume to escape, the entire 
column of tubular fluid is shifted toward the distal end 
of the nephron, so that the Al peak that was originally 
near the sodium reabsorption site is now moved 
downstream, while 
is now opposite 
concentration. The 
tubular fluid of low Al concentration 
the site of the previous Al maximum 
column of tubular fluid then remains 
stationary for a further 5 min in that position allowing 
further excretory and reabsorptive processes to take 
place. The pattern depicted in Figure 5 shows the 
composite effect of the second pattern superimposed on 
the first at the end of the experiment. It can be seen 
that further Al excretion has occurred near the sodium 
reabsorption site during the second half of the 
stop-flow, confirming the data of the regular stop-flows. 
Thus, the plateau of Al excretion from point -50 to 0% is 
formed by the Al/creatinine ratio present distally in the 
second half of the experiment replicating that in the 
first half, even though there was a low Al/creatinine 
ratio present initially. 
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SECTION C 
TOXIC EFFECTS OF ALUMINIUM 
ON THE DNA 
OF KIDNEY CELLS IN CULTURE 
110 
SYNOPSIS 
It is known that renal 
(Al) accumulation and 
kidney itself is not 
failure may lead to systemic aluminium 
toxicity. The effect of Al on the 
well established. The purpose of this 
section was to investigate the toxic effects of Al in vitro on 
the DNA of pig kidney cell line LLC-PK1/ in an attempt to 
elucidate some of the mechanisms of action. 
DNA synthesis was measured using 3H-TdR incorporation. Over 
increases of both time (9-72 h) and Al concentration (0.01-8.0 
mM)/ 3H-TdR incorporation was diminished. 
evident at concentrations as low as 0.05 mM Al. 
Effects were 
The production of DNA strand breaks was assessed by the 
increase in size of cell nucleoids (ie DNA in supercoiled 
form). Nucleoid size was analyzed in a Coulter Electronics 
Epics 753 Fluorescence Activated Cell Sorter interfaced with 
an MDADSII data acquisition and analysis system. After 90 min 
incubation with Al (over the concentration range 0.001-32 mM)/ 
an increase in nucleoid size was noted at concentrations above 
0.05 mM. 
The data demonstrate that Al exerts an effect on kidney cells 
in vitro which is expressed as diminished DNA synthesis and 
production of DNA strand breaks. These effects on DNA may have 
important long-term implications on various disease states 
associated with Al toxicity. 
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1. INTRODUCTION 
1.1. Effects of aluminium on the kidney 
A number of disease 
renal osteodystrophy 
conditions, including 
and anaemia are 
dialysis dementia, 
associated with Al 
accumulation, particularly in the setting of renal failure 
(Monteagudo et al. 1989). While renal impairment is a major 
determinant in the retention and accumulation of the element 
(Monteagudo et al. 1988), the effect of Al on the kidney 
itself has not been extensively documented. 
Anatomically, using ion microscopy and X-ray microanalysis, Al 
has been shown to be concentrated inside the kidney proximal 
tubular cell lysosomes (de Galle 1981). Functional rat kidney 
lysosome damage caused by Al has also been demonstrated (Stein 
et al. 1987), and supports the localisation of the element in 
the kidney. Tissue analysis of dogs chronically injected with 
Al for 3-5 weeks demonstrated the kidney (together with the 
liver and spleen) as accumulating the greatest amount of the 
element (Henry et al. 1984). 
At a functional level, rats injected intraperitoneally with Al 
had loss of renal concentrating ability compared with controls 
(Braunlich et al. 1986). This functional impairment was 
confirmed by Henry et al. (1984), who showed increases in 
serum creatinine, and decreases in exogenous creatinine 
clearance, after chronic injection of dogs with Al. 
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1.2. LLC-PKl cell line 
The purpose of this study was specifically to examine Al 
effects on DNA. The use of an in vitro system was considered 
appropriate for this purpose. The use of cell cultures, in 
general, allows the exclusion of many extraneous factors from 
the research in question. It is also useful in toxicological 
studies when the toxin is known not to be transformed by 
metabolic processes. It also reduces the need to engage in 
animal experimentation. 
The choice of this particular LLC-PKl cell line was made for a 
number of reasons (Hull et al. 1976). Firstly, these cells are 
of pig kidney origin and thus are pertinent to the work of the 
previous section where Al excretion by the pig kidney was 
demonstrated. Secondly, these cells represent a homogenous 
cell population with features of proximal tubular cells, and 
are well characterised (Cantiello et al. 1986; Holohan et al. 
1988). Finally, the ability of these cells to grow in serum 
free conditions has been previously established (Hull et al. 
1976) and this was of importance during the actual experiments 
in order to minimise Al binding to serum. 
1.3. Effects of aluminium on DNA 
It has been known for some time that a relationship exists 
between Al and DNA. 
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1.3.1. Localisation of aluminium on DNA 
Berlyne et al. (1972) noted that rats severely intoxicated 
with Al had a marked reduction in the number of mitoses of the 
stratum basale of the corneal epithelium suggestive of 
decreased cell division and possibly a DNA effect. Intrathecal 
administration of Al to cats and rabbits showed Al to be 
histochemically demonstrable on nuclear chromatin (De Boni et 
al. 1974). 
Al, incubated for 2 h in the salivary gland cells of the black 
fly Simulium vittatum, gained intracellular access and bound 
to chromatin with subsequent inhibition of ecdysterone induced 
"puffing'' in 7 out of 9 chromosomal sites ( Sanderson et al. 
1982). Further support for Al localisation on DNA was provided 
by Dyrssen et al. (1987) who used both potentiometric 
titration and dialysis to show that in vitro Al ion binds to 
DNA obtained from calf thymus. It has been demonstrated that 
Al has cytotoxic effects on the the root-tip of Allium 
sativum, with mitotic depression which is associated with 
decreased DNA synthesis (Roy et al. 1989). Thus, there would 
seem to be a consistent effect of Al in attaching to DNA 
across a broad spectrum of biological systems. 
It has been suggested that Al might complex irreversibly to 
polyphosphates of chromatid DNA in the cell nucleus (MacDonald 
and Martin 1988). In support of this, the nucleus has been 
noted to have the highest phosphate density of any cellular 
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organelle due to DNA and RNA phosphate content; concentrations 
of phosphate are 2,10, and 50 mmol/L in plasma, cytosol and 
the nucleus respectively (Lukiw et al. 1989). 
1.3.2. DNA strand breaks and nucleoids 
Nucleoids may be described as DNA in supercoiled form, present 
as protein-depleted nuclei, formed by cell lysis in the 
presence of detergent and high salt (Cook and Brazell 1976; 
Olive et al. 1986). Nucleoids lack histones but retain DNA 
organisation as a series of repetitive loops in a supercoiled 
conformation (Vaughan et al. 1990). Toxic damage to DNA leads 
to strand breaks which allow the relaxation of DNA 
superhelical structures with a consequent expansion of 
nucleoid size (Johnstone 1984). Assessment of nucleoid size 
does not give an absolute measure of the number of DNA strand 
breaks but rather indicates the relative change in size 
between two samples (Lipetz et al. 1982). The value of 
assessing supercoiled DNA damage is that it provides 
information both functionally ( as it is the basic repeating 
unit of DNA replication), and in terms of structure ( as it is 
physically defined) (Vaughan et al. 1990). 
Nucleoid size can be assessed in various ways. Early 
techniques have used sucrose gradient sedimentation, where the 
larger nucleoids migrate more slowly than controls and are 
represented as a separate band in a test tube (Cook and 
Brazell 1976). This technique is influenced by viscosity, 
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particle density and structure as well as size. Other 
techniques have involved the use of DNA elution from filters, 
which requires bulk samples of cells (Vaughan et al. 1990). 
A more recent method of measuring nucleoid size involves using 
a flow cytometer ( FCM) , such as the Epics 753 Fluorescence 
Activated Cell Sorter used in this work. The increase in 
nucleoid size presents a greater area for laser interaction, 
leading to an increase in light scatter being found in the 
forward angle light scatter ( FALS) detector and which has been 
empirically related to particle size (Mullaney and Dean 1970; 
Loken and Stall 1982). Compared with the sucrose gradient 
sedimentation technique which represents pooled data gathered 
from a band of nucleoid derived material in a test-tube, the 
flow cytometer produces data individually gathered from 
thousands of nucleoids (Milner et al. 1987). 
1.4. Flow cytometer 
A flow cytometer (FCM) uses techniques of fairly recent origin 
which incorporate methodologies from laser technology, 
fluidics, computer science, and various fluorochrome and 
biochemical techniques. Such instrumentation allows for rapid 
quantitative analysis of cells or particles, as they pass 
singly through a laser beam, from which data are obtained and 
multivariate histograms can be derived (Carter and Meyer 
1990). 
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1.4.1. Flow cytometer principles 
The basic components (Figure 6) of a FCM are as follows 
(Carter and Meyer 1990): 
a) Suitably prepared particles are injected into the flow 
chamber, where they enter a fast-moving liquid ("sheath 
fluid'') which by a process of hydrodynamic focussing 
forces the individual particles into a single file. 
b) The particles then pass individually across a laser beam 
where various interactions may occur. These changes are 
noted by photomultiplier tubes (PMTs) which are connected 
to computer data acquisition systems. 
1.4.2. Flow cytometer parameters 
The instrument is complex and capable of diverse functions. 
Only the parameters used in this work viz particle count; 
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FIGURE 6: The operative components of the flow 
cytometer. 
a) Particle count. 
The passage of particles through the laser beam generates a 
signal which allows for their counting. Thus the number of 
particles processed can be precisely quantified. 
b) Fluorescence. 
Various fluorescent substances, such as ethidium bromide (EB) 
intercalate with double-stranded DNA. Their fluorescence 
emission on laser stimulation allows for the identification of 
DNA in the particles. Thus, 
extraneous particulate matter 
by using this 
which does not 
parameter other 
fluoresce (and 
therefore does not contain DNA) can be excluded from analysis. 
The use of EB in assessing nucleoid size is also of value as 
the compaction of DNA supercoils caused by the EB further 
enhances the sensitivity of this measurement (Vaughan et al. 
1990). The same EB concentration was used in all our 
experiments to make this effect a constant one. 
c) Forward angle light scatter (FALS). 
The principle of light scatter used in FCM is analogous to the 
dark field illumination technique used in conventional 
microscopy which recognises cells as a result of their light 
scattering properties. As a particle passes through the laser 
beam, light is scattered from the particle in various 
directions. The light scattered in the forward direction (ie 
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in the direction the laser beam light is travelling) is caused 
mostly by diffraction. Particles of different sizes generate 
different scatter patterns. The total amount of light 
scattered in the forward direction (FALS) is directly related 
to particle size (Mullaney and Dean 1970; Loken and Stall 
1982). 
2. METHODS 
2.1. Establishment of cell line 
A pig kidney adherent epithelial cell line (LLC-PKl) was 
obtained from a cell repository (American Tissue Culture 
Collection Cat No CL 101). This is a homogenous cell line 
with characteristics of proximal tubular cells (Hull et al. 
1976; Cantiello et al. 1986; Holohan et al. 1988). The cells 
were grown in M199 media (Cat No P06, Highveld Biological 
(Pty) Ltd, Johannesburg) supplemented with 3% fetal calf 
serum. As Al binds to proteins and phosphate it was necessary 
for the experiments to quantify cell growth characteristics 
both in serum free (-S) and phosphate free (-Pi) media 
(constituents listed on page 245a). The ability of these 
cells to grow in serum-free conditions has been previously 
established (Hull et al. 1976). 
2.2. DNA synthesis 
DNA synthesis was measured using 3 H-TdR based on a previously 
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described method (Bradley 1980). 
LLC-PKl cells were plated at a concentration of 50 000 
cells/100µ1 volume of (-Pi-S) media in 96 well plates. 100µ1 
of Al containing medium, to produce a final arbitrary dose 
range of 0.01-8 mM, or pH matched (-Pi-S) media as controls, 
was added to each well. Tritiated thymidine (specific 
activity 20 Ci/mmol, New England Nuclear) was added to each 
well at the beginning of the experiment at a concentration of 
2 µCi in 50 µl of media. 
At the end of the experiment EDTA-trypsin was added and the 
cells collected and washed three times with water using a cell 
harvester. The filter papers containing the harvested cells 
were dried, placed in Aquagel (Chemlab Ltd) and measured in a 
Tri Carb 300 Scintillation Counter (Packard Instrument Co 
Inc., Illinois, USA). The 3 H-TdR content of the cells was 
assayed at 9, 12, 24, 48 and 72 hours, at least in triplicate. 
f 
The results obtained represent the cumulative incorporation of 
3 H-TdR into the cells. 
2.3. DNA strand breaks 
Nucleoid size as a measure of DNA strand breaks was analyzed 
based on a previously described method (Vaughan et al. 1990). 
LLC-PKl cells in (-Pi-S) media were filtered through a 72µ 
polypropylene mesh to produce a single cell suspension. The 
cells were then distributed into Eppendorf tubes in a volume 
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of 0.5 ml cell suspension/tube. Al, made up in (-Pi-S) media, 
to produce a final arbitrary dose range of 0.001-32 mM (or pH 
matched media as controls) was then added in a volume of 0.5 
ml at 5 min intervals (in order to standardise the timing of 
each tube precisely) so that the final tube volume was 1 ml. 
The Eppendorf tubes were incubated for 90 min in a CO2 
incubator (Model 3614, Forma Scientific Inc., Marietta, Ohio, 
USA). The cells were washed in (-Pi-S) media twice and to the 
cell pellet was added 1 ml ice cold lysis buffer (containing 
2M sodium chloride, 10 mM TRIS, 10 mM disodium EDTA, and 0.5% 
Triton-X 100) in order to produce nucleoids. After being 
maintained at O °C for 30 min 0.1 ml ethidium bromide (made up 
in water at a concentration of 0.5 mg/ml) was added. Tubes 
were then kept on ice for 90 s to allow for dye equilibration 
and then read on the flow cytometer. 
The nucleoid size was analyzed in a flow cytometer (FCM) ie 
the Epics 753 Fluorescence Activated Cell Sorter (Coulter, 
Hialeah, Florida, USA) interfaced with an MDADSII data 
acquisition and analysis system. 
The FCM operating parameters were as follows. Argon ion laser 
line at 488 nm (250 mW) was used for excitation. The particles 
were processed through a 150µ flow cell tip at a flow rate 
less than 400 particles/second. The data on forward angle 
light scatter (FALS) and fluorescence emission (using a 610 nm 
band pass filter) were collected, amplified and scaled to 
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generate multiparameter histograms. The fluorescence emission 
was gated to exclude non-DNA particles, and subsequently 
analysis gates were set on FALS to determine the mean channel 
for each specimen. After an equilibration period of 20 s a 
minimum of 15 000 particles were analyzed for each histogram 
generated. 
3. RESULTS 
3.1. Establishment of cell line 
Figure 7 demonstrates the growth of the cells in (-S) and 
(-Pi) conditions up to 72 hours. Cell proliferation continues 
to take place in (-S-Pi) conditions. 
3.2. DNA synthesis 
The 3 H-TdR assay is a sensitive indicator of thymidine 
incorporation and indicates the rate of DNA synthesis. Figure 
8 shows that at 0.01 mM Al no difference between the Al and 
control groups could be observed up to 72h. However, 
beginning at 0.05 mM Al the rate of thymidine incorporation by 
the cells begins to decrease. From a concentration of 0.05 to 
1.0 mM Al, thymidine incorporation was decreased in the Al 
group. At the 2.0-8.0 mM Al range there was virtually no 
incorporation of 3 H-TdR in the Al group, while in the pH 
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FIGURE 7: Cell growth of LLC-PK1 in 
serum (S) and phosphate (P) free 
conditions for 72 h. 
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FIGURE 8: Cumulative incorporation of 
3H-TdR in cultured kidney cells from 
GO 
9-72 hours. Al treated and control groups 
are shown by dashed and continuous lines, 
respectively. 
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3.3. DNA strand breaks 
Figure 9 demonstrates the mean forward light scatter channel 
(representing nucleoid size) of each Al sample as a percentage 
of its pH matched control. There was little if any increase 
in nucleoid size compared with controls from concentrations 
0.001-0.05 mM. At concentrations greater than 0.05 mM Al there 
was an increase in nucleoid size relative to controls. 
The data were fitted using a modified (Dr I Havlik, personal 
communication) Michaelis-Menten equation 
where 
Smax • C 
s = 
Qso + C 
s represents relative nucleoid size compared to 
controls; 
Subscripts Smax and So represent the maximal 
nucleoid size, and the extrapolated nucleoid size at 
zero Al concentration, respectively; 
Qso is the value of Al concentration (in mM) when 
half the maximal effect (Smax) is achieved. 
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FIGURE 9: Nuc!eold size measured by the mean 
gate of the forward light scatter at various 
Al concentrations (0.001-32 mM), expressed as 
a percentages of pH-matched controls. The 







For clarity, the data were also logarithmically transformed, 
and are displayed as an insert in the main graph. The data 
were fitted using Enzfitter software (Biosoft, Cambridge, UK), 
a Marquart algorithm (Leatherbarrow 1987) and the reduced chi-
square as the iterative parameter. The maximal nucleoid size 
(Sma=) was 76 (SE~ 9.6) % greater than the control size. The 
Al concentration at which the nucleoid size was half the 
maximal size (Qso) was 3.44 (SE~ 1.50) mM. Using the fitted 
data the origin of the curve representing the extrapolated 
value (So) was 99 (SE+ 3.5)% . 
Figure 10 a-m) illustrates a series of 3-D histograms of Al 
treated nucleoids and their pH matched controls. No 
discernible change could be noted between the Al and control 
samples at low concentrations, whereas obvious changes could 
be noted between the treated and control samples at higher 
concentrations (Figure 10). The Al treated 3-D histograms at 
higher concentrations (Figure 10) illustrate the increases in 
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FIGURE 1 Oa: 3-D histograms of 32 mM 
Al nucleoids and control. The height of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axts 
represents forward light scatter with the 
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FIGURE 1 Oc: 3-D histograms of 8 mM 
Al nucleoids and control. The height of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axts 
represents forward light scatter with the 
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FIGURE 1 Oe: 3-D histograms of 4 mM 
Al nucleoids and control. The height of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axis 
represents forward light scatter with the 
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FIGURE 1 Of: 3-D histograms of 2 mM 
Al nucleoids and control. The height of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axts 
represents forward light scatter with the 
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FIGURE 1 Og: 3-D histograms of 1 mM 
Al nucleotds and control. The height of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axls 
represents forward light scatter with the 
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FIGURE 1 Oh: 3-D histograms of 0.5 mM 
Al nucleotds and control. The helght of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axts 
represents forward ltght scatter wtth the 













·---··-·-·'· _._. ____ ,..-.,/··-----··---... __ , 







------ -·- ;"·-::::r,.,\,-. ..._.. ___ ... __ ._ 
___ ::...-=-::-·-.. 
FIGURE 1 Ot: 3-D histograms of 0.1 mM 
Al nucleolds and control. The height of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axis 
represents forward ltght scatter with the 
particle stze lncreastng into the distance. 
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FIGURE 1 Of: 3-D histograms of 0.05 mM 
Al nucleoids and control. The helght of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axts demonstrates the 
range of fluorescence of DNA; and the Z-axts 
represents forward ltght scatter with the 
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FIGURE 1 Ok: 3-D htstograms of 0.025 mM 
Al nucleoids and control. The height of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axis 
represents forward light scatter with the 
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FIGURE 101: 3-D histograms of 0.01 mM 
Al nucleoids and control. The height of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axts 
represents forward light scatter wtth the 
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FIGURE 1 Om : 3-D histograms of 0.001 mM 
Al nucleotds and control. The height of 
the peaks on the Y-axis demonstrates the 
particle number; the X-axis demonstrates the 
range of fluorescence of DNA; and the Z-axls 
represents forward llght scatter with the 
particle size increasing Into the distance. 
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4. DISCUSSION 
4.1. Discussion of literature 
The role of kidney disease in causing Al toxicity has been 
previously described and relates to impaired excretion of the 
element (Monteagudo et al. 1988; Monteagudo et al. 1989). The 
converse role of Al toxicity in causing renal disease has not 
been fully explored. Al toxicity could possibly play a role in 
damaging kidney tissue and further aggravate pre-existing 
renal disease. The role of Al as a toxic agent in various cell 
types other than kidney, such as brain, haemopoietic cells, 
and bone is well known. 
Previous work has demonstrated tissue accumulation, as well as 
functional effects, of Al on the kidney. Al has been shown to 
accumulate in the kidney (Henry et al. 1984; de Galle 1981). 
Kidney function has been found to be impaired in the presence 
of Al, both in terms of concentrating ability (Braunlich et 
al. 1986), as well as creatinine clearance (Henry et al. 
1984). However, Cacini and Yokel (1988) did not find Al at 
concentrations of 1 mM over 2 h to be toxic in incubated 
slices of rabbit renal cortex. 
It is suggested that some of the cellular and molecular 
mechanisms of Al action may explain its toxicity. 
shown to bind to chromosomal material (de Boni 
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Al has been 
1974); to 
interfere with DNA and RNA (Siegel 1985); to inhibit 
ADP-ribosylation (Crapper McLachlan et al. 1983); to inhibit 
brain glycolysis (Lai and Blass 1984); to inhibit 
hydropteridine reductase in erythrocytes (Altmann et al. 
1987); to inhibit calmodulin (Suhayda and Haug 1984); possibly 
to impair the inositol phosphate system (Birchall and Chappell 
1988); to inhibit magnesium dependent enzymes (Macdonald and 
Martin 1988); and to interact with calcium channel blockers 
(Provan and Yokel 1988). The cellular site of toxic action of 
Al is obviously not clearly defined although DNA damage has 
clearly been implicated. Many of the above processes may 
interfere with DNA synthesis, or cause DNA strand breaks, by 
secondary mechanisms. 
4.2. Discussion of experiments 
These experiments were performed in serum and phosphate free 
(-S-Pi) conditions as both these substances are known to bind 
to Al and thus reduce its biological availability. LLC-PKl 
cells have previously been shown to adapt to growth in serum 
free conditions (Hull et al. 1976). Cell growth continued for 
up to 72 hours in (-Pi-S) media (Figure 7). This growth in (-
Pi-S) conditions was confirmed in the 3 H-TdR experiments which 
showed continued incorporation up to 72 hours in the controls. 
In the first experiment, 3 H-TdR incorporation was used as a 
marker of continued DNA synthesis 
proliferation. The data demonstrate 
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and subsequent 
that at an 
cell 
Al 
concentration of 0.05 mM an effect on 3 H-TdR incorporation 
became more prominent in the later stages of the experiment. 
Little, if any, effect could be seen at 9 and 12 hours. At 
higher concentrations of Al, toxic effects were more prominent 
at earlier times in the experiment. It 
speculate that exposure to very much smaller 
years could exert a similar toxic effect. 
is possible to 
doses of Al over 
The second experiment demonstrated the effect of Al on 
nucleoid size as a marker of DNA strand-breaks. The mean gate 
on the FALS detector, representing particle size for each Al 
concentration, as a percentage of controls is shown in Figure 
9. At concentrations greater than 0.05 mM increases in 
particle size were noted with a calculated eventual maximal 
nucleoid size of 76 + 9.6% greater than control (which is 
taken as 100%). This increase in nucleoid size, particularly 
in the dose dependent manner shown, is indicative of the 
effect of Al in causing DNA strand-breaks. 
Figure 10 a-m) shows 
additional information 
in Figure 9. 
a series of 3-D histograms providing 
on the nucleoid particles represented 
These 3-D histograms provide a pictorial representation of the 
number, degree of fluorescence, and size of the particles in 
question. Thus, they provide qualitative, rather than 
quantitative, information. Due to differences in the number of 
particles present in certain peaks the scaling was adjusted to 
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best represent that particular graph. At the ,,deepest" edge of 
the Z-axis, a so-called ,,horizon line,, is evident in all the 
graphs. Peaks on this ,,horizon line', represent a summation of 
all particles larger than those represented in the histogram 
range of the Z-axis. 
Inspection of the series of 3-D histograms illustrates the 
differences at higher Al concentrations where there appear to 
be greater numbers of larger particles compared with controls. 
At lower Al concentrations the differences between the treated 
and control groups are less marked. 
The data found in this section represent the results of in 
vitro experiments. The concentrations of Al used in vitro were 
higher than those encountered in clinical practice. Higher 
concentrations were used due to the very short period of 
exposure in vitro (hours) compared with clinical exposure 
(often years). Moreover, despite the (-Pi-S) conditions of the 
experiment Al binds to substances, other than serum and 
phosphate, in in vitro conditions thus reducing biological 
availability and effect. 
I~ the clinical setting, patients with renal failure often 
have blood levels of 200 µg/L or higher (Savory 1985). Blood 
levels of 1730 µg/L have been recorded (De Broe et al. 1984). 
However, the level of Al in the blood may bear little direct 
relationship to the concentration of Al at its cellular site 
of toxic action in the body. 
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This study of the toxic mechanisms of Al on kidney cells may 
be of importance firstly by increasing knowledge of clinical 
syndromes of Al toxicity and secondly by providing information 
on cell biology and molecular mechanisms. The process by which 
Al exerts an effect on DNA synthesis and DNA strand breaks is 






This thesis has studied aspects of the interaction 
between aluminium and the kidney. The work has addressed 
two major issues. 
Firstly, a site for aluminium excretion 
tubule of the pig kidney was identified. 
kidney in excreting Al is critical 
by the distal 
The role of the 
as has been 
demonstrated clinically. Possible avenues for further 
research into the mechanisms involved in such excretion, 




the role of pharmacological agents 
excretory process, are suggested by 
in 
the 
Secondly, Al interacts with DNA causing diminished 
synthesis, and production of DNA strand-breaks, in a 
kidney cell system in vitro. This effect of Al on DNA 
throws light on the mechanisms of toxicity of the element 
in biological systems. How it is that aluminium exerts 
the effects on DNA that have been described in this 
thesis remain to be determined. 
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APPENDIX 
DATA FROM SECTION B 
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INTRODUCTION TO APPENDIX 
The Appendix deals with data from Section B. This 
introduction is inserted to facilitate the reading 
of this data. 
SUB-INDEX OF APPENDIX PAGE 
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FRACTIONAL EXCRETION OF FILTERED CREATININE .. 241 
SPECIFIC APPENDIX ABBREVIATIONS 
1. N/A - not available 
2. N/D - non-detectable 
3. S-F(I) - refers to interrupted stop-flow 
4. S-F(R) - refers to regular stop-flow 
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SUMMARY OF EXPERIMENTS 
Pig s - F - Type Substance 
I A - R Hydrochloric 
B - R Acid 
II A - R Hydrochloric 
B - R Acid 
III A - R Al lmg/kg bw 
B - R 
C - R 
IV A - R Al O.Smg/kg bw 
B - R 
C - R 
V A - R Al O.lmg/kg bw 
B - I 
C - I 
VI A - R Al O.lmg/kg bw 
B - R 
C - R 
VII A - R Al O.lmg/kg bw 
B - R 
C - R 
VIII A - R Al O.lmg/kg bw 
B - I 
C - R 






WEIGHT: 20 KG 
TIME TIME FREE-FLOW STOP-FLOW 
(Minutes) ( a .m) SAMPLE SAMPLE 
-60 9.15 1 
-50 9.25 2 
-40 9.35 3 
-30 9.45 4 
-25 9.50 S-F.I.A(R) 
-15 10.00 5 
- 5 10.10 6 
0 10.15 HYDROCHLORIC ACID 
INJECTED 
5 10.20 7 
15 10.30 8 
30 10.45 S-F.I.B(R) 
35 10.50 9 




WEIGHT: 25 KG 
TIME TIME 































WEIGHT: 20 KG 
TIME TIME FREE-FLOW STOP-FLOW 
(minutes) (a. m) SAMPLE SAMPLE 
-60 9.15 1 
N/A 2 
-35 9.40 3 
N/A 4 
N/A S-F.III.A(R) 
0 10.15 ALUMINIUM 
INJECTED 
15 10.30 5 
20 10.35 6 
N/A S-F.III.B(R) 
45 11. 00 7 
50 11. 05 8 
N/A S-F.III.C(R) 




WEIGHT: 25 KG 
TIME TIME FREE-FLOW STOP-FLOW 
(minutes) ( a.m) SAMPLE SAMPLE 
-15 9.00 1 
-10 9.05 2 
0 9.15 ALUMINIUM 
INJECTED 
10 9.25 3 
15 9.30 4 
25 9.40 S-F.IV.A(R) 
35 9.50 5 
40 9.55 6 
50 10.05 S-F.IV.B(R) 
60 10.15 7 
85 10.40 8 




WEIGHT: 25 KG 
TIME TIME FREE-FLOW STOP-FLOW 
(minutes) ( a .m) SAMPLE SAMPLE 
-20 8.45 1 
-10 8.55 2 
0 9.05 ALUMINIUM 
INJECTED 
5 9.10 3 
15 9.20 4 
20 9.25 S-F.V.A(R) 
30 9.35 5 
35 9.40 6 
40 9.45 S-F.V.B(I) 
55 10.00 7 




WEIGHT: 40 KG 
TIME TIME FREE-FLOW STOP-FLOW 
(minutes) (a. m) SAMPLE SAMPLE 
-40 9.35 1 
-30 9.45 2 
-25 9.50 S-F.VI.A(R) 
-10 10.05 3 
0 10.15 ALUMINIUM 
INJECTED 
5 10.20 4 
10 10.25 5 
20 10.35 S-F.VI.B(R) 
35 10.50 6 
40 10.55 7 
55 11.10 S-F.VI.C(R) 




WEIGHT: 19 KG 
TIME TIME FREE-FLOW STOP-FLOW 
(minutes) ( a .m) SAMPLE SAMPLE 
-35 8.55 1 
-25 9.05 2 
-20 9.10 S-F.VII.A(R) 
-10 9.20 3 
0 9.30 ALUMINIUM 
INJECTED 
5 9.35 4 
10 9.40 5 
15 9.45 S-F.VII.B(R) 
25 9.55 6 
30 10.00 7 
40 10.10 S-F.VII.C(R) 
55 10.25 8 




WEIGHT: 34 KG 
TIME TIME FREE-FLOW STOP-FLOW 
(minutes) (a.m) SAMPLE SAMPLE 
-10 9.30 1 
- 5 9.35 2 
0 9.40 ALUMINIUM 
INJECTED 
5 9.45 3 
10 9.50 4 
20 10.00 S-F.VIII.A(R) 
25 10.05 5 
30 10.10 6 
35 10.15 S-F.VIII.B( I) 
50 10.30 7 
70 10.50 S-F.VIII.C(R) 
80 11.00 8 
85 11. 05 9 
90 11.10 S-F.VIII.D(I) 
105 11.25 10 
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SINGLE KIDNEY CLEARANCE 
161 
SINGLE KIDNEY CREATININE CLEARANCE 
ALL SAMPLES COLLECTED OVER 5 MINUTES 
PIG I 
SAMPLE URINE URINARY PLASMA 
VOLUME CREATININE CREATININE 
( ml) (µmol/L) (µmol/L) 
1 29 644 131 
2 16 756 131 
3 47 278 131 
4 57 277 131 
5 32 335 136 
6 25 413 142 
HYDROCHLORIC ACID INJECTED 
7 20 509 140 
8 51 274 140 
9 46 270 141 
10 30 349 147 
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SINGLE KIDNEY CREATININE CLEARANCE 
ALL SAMPLES COLLECTED OVER 5 MINUTES 
PIG II 
SAMPLE URINE URINARY 
VOLUME CREATININE 
( ml) (µmol/L) 
1 29 420 
2 34 366 
3 34 335 
4 38 303 
HYDROCHLORIC ACID INJECTED 
5 48 249 
6 44 265 
7 43 267 













SINGLE KIDNEY CREATININE CLEARANCE 
ALL SAMPLES COLLECTED OVER 5 MINUTES 
PIG III 
SAMPLE URINE URINARY 
VOLUME CREATITINE 
( ml) (µmol/L) 
1 30 392 
2 31 422 
3 33 400 
4 24 524 
ALUMINIUM INJECTED 
5 44 319 
6 23 504 
7 31 508 
8 41 382 














SINGLE KIDNEY CREATININE CLEARANCE 
ALL SAMPLES COLLECTED OVER 5 MINUTES 
PIG IV 
SAMPLE URINE URINARY 
VOLUME CREATININE 
( ml) (µmol/L) 
1 30 439 
2 23 538 
ALUMINIUM INJECTED 
3 30 501 
4 26 496 
5 23 673 
6 20 755 
7 44 345 













SINGLE KIDNEY CREATININE CLEARANCE 
ALL SAMPLES COLLECTED OVER 5 MINUTES 
PIG V 
SAMPLE URINE URINARY 
VOLUME CREATININE 
( ml) (µmol/L) 
1 47 382 
2 31 472 
ALUMINIUM INJECTED 
3 16 564 
4 24 581 
5 41 421 
6 36 477 












SINGLE KIDNEY CREATININE CLEARANCE 
ALL SAMPLES COLLECTED OVER 5 MINUTES 
PIG VI 
SAMPLE URINE URINARY 
VOLUME CREATININE 
( ml) (µmol/L) 
1 22 1086 
2 30 706 
3 39 532 
ALUMINIUM INJECTED 
4 45 512 
5 42 506 
6 46 480 
7 44 468 













SINGLE KIDNEY CREATININE CLEARANCE 
ALL SAMPLES COLLECTED OVER 5 MINUTES 
PIG VII 
SAMPLE URINE URINARY 
VOLUME CREATININE 
( ml) (µmol/L) 
1 42 243 
2 33 290 
3 44 236 
ALUMINIUM INJECTED 
4 29 344 
5 28 314 
6 25 346 
7 22 444 
8 35 286 














SINGLE KIDNEY CREATININE CLEARANCE 
ALL SAMPLES COLLECTED OVER 5 MINUTES 
PIG VIII 
SAMPLE URINE URINARY 
VOLUME CREATININE 
( ml) (µmol/L) 
1 40 390 
2 47 432 
ALUMINIUM INJECTED 
3 18 842 
4 18 926 
5 18 950 
6 13 1200 
7 15 1074 
8 23 738 
9 18 796 















SINGLE KIDNEY INULIN CLEARANCE 
ALL SAMPLES COLLECTED OVER 5 MINUTES 
PIG VIII 
SAMPLE URINE URINARY 
VOLUME INULIN 
( ml) (mg/dL) 
1 40 140 
2 47 144 
ALUMINIUM INJECTED 
3 18 252 
4 18 251 
5 18 224 
6 13 263 
7 15 238 
8 23 133 
9 18 170 






















































































STOP-FLOW DATA - I.A 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 52 0.78 371 
2 34 0.78 504 
3 22 0.69 511 
4 13 0.54 483 
5 12 0.41 511 
6 20 0.36 455 
7 N/A 0.30 476 
8 N/A 0.41 441 
9 N/A 0.31 434 
10 54 0.28 399 
11 64 0.22 364 
12 0.22 343 
13 0.19 350 
14 0.17 350 
15 0.17 357 
16 0.16 336 
17 0.19 392 
18 0.20 350 
19 0.20 336 
20 0.28 294 
173 
PIG I 
STOP-FLOW DATA - I.A 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 N/D 2.70 
2 " 1. 97 
3 " 1. 43 
4 " 0.77 
5 " 0.37 
6 " 0.52 
7 " 0.88 
8 " 1. 45 
9 " 1. 66 
10 " 2.05 
11 " 2.53 
12 " 2.88 
13 " 2.95 
14 " 2.97 
15 " 2.94 
16 " 2.83 
17 " 2.86 
18 " 2.94 
19 " 3.00 
20 " 3.21 
174 
PIG I 
STOP-FLOW DATA - I.B 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1.05 1. 05 
2 1.19 2.24 
3 1.16 3.40 
4 0.83 4.23 
5 0.99 5.22 
6 0.85 6.07 
7 0.72 6.79 
8 0.95 7.74 
9 0.81 8.55 
10 1.11 9.66 
11 0.85 10.51 
12 0.93 11.44 
13 0.74 12.18 
14 1.03 13.21 
15 0.86 14.07 
16 0.57 14.64 
17 0.62 15.26 
18 0.74 16.00 
19 0.56 16.56 
20 1. 57 18.13 
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PIG I 
STOP-FLOW DATA - I.B 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 39 0.30 508 
2 36 0.33 494 
3 24 0.28 528 
4 25 0.23 540 
5 9 0.23 542 
6 7 0.22 506 
7 9 0.25 502 
8 14 0.23 524 
9 18 0.23 508 
10 25 0.22 520 
11 0.19 530 
12 0.19 478 
13 0.19 484 
14 0.16 474 
15 0.17 512 
16 0.19 492 
17 0.19 496 
18 0.19 512 
19 0.20 574 
20 0.19 678 
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PIG I 
STOP-FLOW DATA - I.B 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 N/D 2.20 
2 " 1. 97 
3 " 1. 51 
4 " 1. 08 
5 " 0.64 
6 " 0.41 
7 " 0.43 
8 " 0.63 
9 " 0.87 
10 " 1. 42 
11 " 1. 82 
12 " 2.24 
13 " 2.29 
14 " 2.31 
15 " 2.30 
16 " 2.30 
17 " 2.33 
18 " 2.36 
19 " 2.31 
20 " 2.37 
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PIG II 
STOP-FLOW DATA - II.A 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1. 20 1. 20 
2 1. 44 2.64 
3 1. 68 4.32 
4 1. 47 5.79 
5 1.44 7.23 
6 1.51 8.74 
7 1.76 10.50 
8 1. 40 11.90 
9 1.66 13.56 
10 1.83 15.39 
11 1. 57 16.96 
12 1.36 18.32 
13 1.57 19.89 
14 1.57 21. 46 
15 1. 62 23.08 
16 0.95 24.03 
17 1. 05 25.08 
18 1. 21 26.29 
19 1.39 27.68 
20 2.11 29.79 
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PIG II 
STOP-FLOW DATA - II.A 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 62 1. 01 354 
2 58 1. 09 356 
3 35 1. 30 536 
4 21 1.15 528 
5 13 1. 09 486 
6 17 0.72 464 
7 36 0.54 438 
8 55 0.50 440 
9 69 0.40 412 
10 64 0.34 370 
11 0.31 362 
12 0.25 394 
13 0.44 388 
14 0.58 342 
15 0.75 320 
16 0.92 304 
17 1.13 284 
18 1. 58 276 
19 1. 46 310 
20 1. 44 260 
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PIG II 
STOP-FLOW DATA - II.A 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 N/D 2.66 
2 " 2.74 
3 " 2.22 
4 " 1.13 
5 " 0.95 
6 " 0.36 
7 " 0.78 
8 " 1. 89 
9 " 2.42 
10 " 2.59 
11 " 2.51 
12 " 2.12 
13 " 2.86 
14 " 2.80 
15 " 3.00 
16 " 3.16 
17 " 3.23 
18 " 4.58 
19 " 3.80 
20 " 3.35 
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PIG II 
STOP-FLOW DATA - II.B 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1. 92 1. 92 
2 2.61 4.53 
3 1. 63 6.16 
4 1. 72 7.88 
5 1. 73 9.61 
6 1. 61 11. 22 
7 1.82 13.04 
8 1. 72 14.76 
9 1. 70 16.46 
10 2.00 18.46 
11 1.13 19.59 
12 1. 49 21. 08 
13 1. 59 22.67 
14 1. 79 24.46 
15 1.27 25.73 
16 1.15 26.88 
17 1. 08 27.96 
18 1. 28 29.24 
19 1.37 30.61 
20 2.69 33.30 
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PIG II 
STOP-FLOW DATA - II.B 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 62 0.23 296 
2 52 0.26 324 
3 31 0.50 408 
4 16 0.21 324 
5 12 0.27 384 
6 17 0.25 404 
7 30 0.28 352 
8 43 0.10 348 
9 52 0.14 318 
10 60 0.09 324 
11 0.18 308 
12 0.20 334 
13 0.25 294 
14 0.29 300 
15 0.33 338 
16 0.73 306 
17 0.44 306 
18 N/A 333 
19 0.59 299 
20 0.61 316 
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PIG II 
STOP-FLOW DATA - II.B 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 N/D 2.92 
2 " 2.90 
3 " 3.84 
4 " 1. 39 
5 " 0.70 
6 " 0.48 
7 " 0.81 
8 " 1.83 
9 " 2.65 
10 " 3.27 
11 " 3.07 
12 " 3.57 
13 " 2.97 
14 " 2.90 
15 " 2.90 
16 " N/A 
17 " 2.93 
18 " N/A 
19 " 3.38 
20 " 3.49 
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PIG III 
STOP-FLOW DATA - III.A 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 2.35 2.35 
2 2.07 4.42 
3 1.77 6.19 
4 1.60 7.79 
5 1.48 9.27 
6 1.38 10.65 
7 1.37 12.02 
8 1.36 13.38 
9 1.36 14.74 
10 1.31 16.05 
11 1.32 17.37 
12 1. 35 18.72 
13 1. 36 20.08 
14 1.36 21.44 
15 1. 34 22.78 
16 1. 31 24.09 
17 1.46 25.55 
18 1.30 26.85 
19 1.40 28.25 
20 1. 51 29.76 
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PIG III 
STOP-FLOW DATA - III.A 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 34 5.13 393 
2 24 5.99 531 
3 14 5.86 546 
4 8 4.73 495 
5 8 3.76 483 
6 18 3.35 477 
7 24 2.57 465 
8 40 1. 69 423 
9 42 1.17 423 
10 38 1. 06 432 
11 1. 08 426 
12 1. 28 435 
13 1. 78 432 
14 2.37 369 
15 2.78 387 
16 3.32 369 
17 3.70 366 
18 3.92 348 
19 4.19 378 
20 4.33 318 
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PIG III 
STOP-FLOW DATA - III.A 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 N/D 2.12 
2 " 1. 78 
3 " 0.98 
4 " 0.41 
5 " 0.21 
6 " 0.71 
7 " 1. 63 
8 " 2.56 
9 " 2.73 
10 " 2.46 
11 " 2.35 
12 " 2.48 
13 " 2.74 
14 ,, 2.56 
15 " 2.74 
16 ,, 2.76 
17 ,, 2.62 
18 " 2.51 
19 ,, 2.57 
20 ,, 2.54 
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PIG III 




































































STOP-FLOW DATA - III.B 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 35 1. 87 405 
2 29 1.89 483 
3 17 1.90 507 
4 8 1. 57 507 
5 5 1. 25 465 
6 12 0.96 447 
7 21 0.75 462 
8 31 0.64 420 
9 39 0.44 378 
10 40 0.50 387 
11 0.49 354 
12 0.73 309 
13 0.85 291 
14 1. 06 312 
15 1. 29 312 
16 1.55 N/A 
17 1. 76 N/A 
18 1.72 303 
19 1. 81 309 
20 1. 87 333 
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PIG III 








































































































































STOP-FLOW DATA - III.C 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 49 1. 63 189 
2 39 2.15 246 
3 24 1. 97 294 
4 16 1. 75 279 
5 11 1. 47 267 
6 13 N/A 255 
7 16 1.06 258 
8 26 0.89 237 
9 42 0.66 228 
10 52 0.49 219 
11 0.41 207 
12 0.52 198 
13 0.58 189 
14 0.70 156 
15 0.78 210 
16 0.90 198 
17 1. 01 183 
18 1. 08 180 
19 1.18 180 
20 1. 34 180 
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PIG III 




































































STOP-FLOW DATA - IV.A 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 2.30 2.30 
2 2.02 4.32 
3 1.81 6.13 
4 1.45 7.58 
5 1. 34 8.92 
6 1. 75 10.67 
7 1. 69 12.36 
8 1.71 14.07 
9 1.84 15.91 
10 1.74 17.65 
11 1. 46 19.11 
12 1.69 20.80 
13 1. 76 22.56 
14 1. 80 24.36 
15 1. 75 26.11 
16 1. 62 27.73 
17 1.64 29.37 
18 1. 87 31. 24 
19 2.09 33.33 
20 3.15 36.48 
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PIG IV 
STOP-FLOW DATA - IV.A 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 46 3.30 546 
2 32 3.79 730 
3 16 3.44 686 
4 10 3.02 644 
5 12 2.70 642 
6 20 2.40 624 
7 38 2.04 556 
8 50 1. 76 528 
9 52 1. 71 502 
10 52 1.69 496 
11 52 1.70 462 
12 56 1.77 440 
13 56 1. 91 414 
14 58 2.14 394 
15 54 2.33 370 
16 60 2.51 352 
17 62 2.77 342 
18 64 3.09 342 
19 56 3.34 340 
20 62 3.77 326 
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PIG IV 




































































STOP-FLOW DATA - IV.B 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 2.25 2.25 
2 1. 90 4.15 
3 1.60 5.75 
4 1.28 7.03 
5 1.24 8.27 
6 1.05 9.32 
7 0.87 10.19 
8 1. 24 11. 43 
9 1. 79 13.22 
10 2.04 15.26 
11 1.31 16.57 
12 1. 32 17.89 
13 1.29 19.18 
14 1. 37 20.55 
15 2.02 22.57 
16 1. 98 24.55 
17 1.97 26.52 
18 2.11 28.63 
19 1. 91 30.54 
20 2.85 33.39 
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PIG IV 
STOP-FLOW DATA - IV.B 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 46 0.72 450 
2 28 0.92 560 
3 20 0.89 524 
4 16 0.75 498 
5 10 0.66 497 
6 10 0.62 469 
7 12 0.66 455 
8 20 0.59 444 
9 30 0.59 428 
10 36 0.39 380 
11 0.33 350 
12 0.33 322 
13 0.33 322 
14 0.36 356 
15 0.36 334 
16 0.33 320 
17 0.36 310 
18 0.49 294 
19 0.53 272 
20 0.59 264 
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PIG IV 








































































































































STOP-FLOW DATA - IV.C 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 37 0.36 534 
2 32 0.36 636 
3 20 0.33 604 
4 11 0.33 560 
5 5 0.33 540 
6 7 0.33 516 
7 15 0.33 486 
8 28 0.30 452 
9 39 0.30 430 
10 45 0.25 400 
11 0.21 404 
12 0.25 384 
13 0.23 380 
14 0.23 346 
15 0.25 322 
16 0.25 320 
17 0.30 316 
18 0.34 316 
19 0.44 318 
20 0.52 328 
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PIG IV 




































































STOP-FLOW DATA - V.A 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 2.21 2.21 
2 1. 74 3.95 
3 1. 54 5.49 
4 1. 32 6.81 
5 1. 41 8.22 
6 1. 41 9.63 
7 1. 57 11. 20 
8 1. 50 12.70 
9 1. 66 14.36 
10 1. 47 15.83 
11 1. 60 17.43 
12 1. 64 19.07 
13 1. 51 20.58 
14 1. 50 22.08 
15 1. 46 23.54 
16 1. 59 25.13 
17 1. 48 26.61 
18 1. 44 28.05 
19 1. 55 29.60 
20 2.52 32.12 
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PIG V 
STOP-FLOW DATA - V.A 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 56 5.12 700 
2 52 5.61 628 
3 34 5.78 696 
4 22 5.49 672 
5 16 4.75 664 
6 16 4.16 665 
7 26 3.53 644 
8 36 2.85 604 
9 50 2.05 556 
10 62 1.65 544 
11 56 1. 42 504 
12 54 1. 37 520 
13 54 1. 45 516 
14 54 1. 79 488 
15 56 1.96 484 
16 54 2.19 456 
17 54 2.36 456 
18 60 2.56 420 
19 62 2.85 416 
20 58 2.99 428 
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PIG V 
STOP-FLOW DATA - V.A 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 43 3.83 
2 70 3.16 
3 92 2.29 
4 100 1.53 
5 88 0.84 
6 72 0.59 
7 70 0.91 
8 54 1. 98 
9 48 2.79 
10 13 3.35 
11 11 3.33 
12 15 3.22 
13 17 3.03 
14 22 3.10 
15 20 3.11 
16 8 3.11 
17 8 3.22 
18 8 3.24 
19 13 3.43 
20 13 3.15 
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PIG V 
STOP-FLOW DATA - V.B 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 2.36 2.36 
2 2.09 4.45 
3 1. 80 6.25 
4 1. 51 7.76 
5 1. 53 9.29 
6 1. 77 11.06 
7 1.84 12.90 
8 1.76 14.66 
9 1. 70 16.36 
10 1. 68 18.04 
11 1. 38 19.42 
12 1. 49 20.91 
13 1. 55 22.46 
14 1. 44 23.90 
15 1. 54 25.44 
16 1. 53 26.97 
17 1. 61 28.58 
18 1. 61 30.19 
19 1. 59 31. 78 
20 2.35 34.13 
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PIG V 
STOP-FLOW DATA - V.B 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 24 1.62 668 
2 26 1. 33 768 
3 20 1. 22 840 
4 14 1.14 856 
5 10 1. 08 882 
6 10 1. 00 800 
7 16 0.94 808 
8 24 0.88 736 
9 36 0.68 684 
10 42 0.68 640 
11 0.57 624 
12 0.68 624 
13 0.66 628 
14 0.77 624 
15 0.85 616 
16 0.94 580 
17 1.11 564 
18 1.34 544 
19 1. 48 524 
20 1. 79 536 
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PIG V 





1 70 1.41 
2 70 2.03 
3 70 1.67 
4 74 1.13 
5 74 0.51 
6 74 0.34 
7 61 0.56 
8 43 1.40 
9 52 2.47 
10 22 3.04 
11 24 3.28 
12 17 2.98 
13 24 3.04 
14 22 2.90 
15 22 2.81 
16 17 3.00 
17 22 3.06 
18 26 3.04 
19 30 3.09 
20 39 3.04 
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PIG V 
STOP-FLOW DATA - v.c 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 2.16 2.16 
2 2.03 4.19 
3 1. 67 5.86 
4 1.57 7.43 
5 2.23 9.66 
6 1. 55 11.21 
7 1. 63 12.84 
8 1. 54 14.38 
9 1. 58 15.96 
10 1.75 17.71 
11 1.46 19.17 
12 1.17 20.34 
13 1. 08 21.42 
14 1. 31 22.73 
15 1.10 23.83 
16 1. 34 25.17 
17 1. 02 26.19 
18 1.06 27.25 
19 1. 39 28.64 
20 2.02 30.66 
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PIG V 
STOP-FLOW DATA - v.c 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mrnol/L) (mg/dL) (µmol/L) 
1 22 1.14 786 
2 28 0.94 864 
3 22 0.91 892 
4 14 0.91 866 
5 10 0.91 846 
6 10 0.85 902 
7 14 0.80 894 
8 22 0.91 812 
9 30 0.68 848 
10 38 0.54 764 
11 0.46 772 
12 0.48 860 
13 0.54 864 
14 0.63 860 
15 0.71 896 
16 0.88 910 
17 1. 05 868 
18 1. 22 780 
19 1.48 824 
20 1. 71 858 
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PIG V 
STOP-FLOW DATA - V.C 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 76 1.26 
2 61 2.61 
3 43 2.20 
4 65 1.55 
5 65 0.76 
6 63 0.54 
7 61 0.67 
8 43 1.60 
9 39 2.39 
10 43 2.93 
11 43 3.23 
12 46 2.23 
13 35 2.99 
14 52 2.93 
15 52 2.92 
16 52 2.70 
17 52 2.71 
18 54 2.59 
19 57 2.61 
20 52 2.59 
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PIG VI 
STOP-FLOW DATA - VI.A 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 2.10 2.10 
2 1. 89 3.99 
3 1.97 5.96 
4 1. 94 7.90 
5 1. 85 9.75 
6 1. 69 11. 44 
7 1. 68 13.12 
8 1.65 14.77 
9 1. 65 16.42 
10 2.01 18.43 
11 1. 98 20.41 
12 1.55 21.96 
13 1. 02 22.98 
14 1. 98 24.96 
15 1. 48 26.44 
16 2.24 28.68 
17 1. 42 30.10 
18 2.14 32.24 
19 1. 45 33.69 
20 2.78 36.47 
211 
PIG VI 
STOP-FLOW DATA - VI.A 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 42 2.87 726 
2 34 3.09 920 
3 24 3.39 1040 
4 13 2.97 936 
5 11 2.57 968 
6 19 2.19 932 
7 28 1.81 802 
8 N/A 1. 55 N/A 
9 51 1. 29 758 
10 55 1.14 720 
11 1.19 768 
12 0.98 700 
13 0.94 758 
14 1. 20 626 
15 1. 02 612 
16 1.10 556 
17 1. 35 512 
18 1. 35 474 
19 1. 55 N/A 
20 1. 74 436 
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PIG VI 
STOP-FLOW DATA - VI.A 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 N/D 2.39 
2 " 2.06 
3 " 1.38 
4 " 0.78 
5 " 0.57 
6 " 0.50 
7 " 1.07 
8 " 2.22 
9 " 2.71 
10 " 3.03 
11 " 3.03 
12 " 3.16 
13 " 3.34 
14 " 3.34 
15 " 3.39 
16 " 3.60 
17 " 3.71 
18 " 3.79 
19 " 3.77 
20 " 3.77 
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STOP-FLOW DATA - VI.B 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1. 82 1. 82 
2 1. 86 3.68 
3 1. 75 5.43 
4 1. 62 7.05 
5 1. 97 9.02 
6 1. 63 10.65 
7 1. 36 12.01 
8 1. 47 13.48 
9 1. 42 14.90 
10 1.74 16.64 
11 1. 50 18.14 
12 1. 63 19.77 
13 1. 60 21.37 
14 1. 81 23.18 
15 1. 62 24.80 
16 1. 60 26.40 
17 1. 62 28.02 
18 1. 73 29.75 
19 2.14 31.89 
20 2.91 34.80 
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STOP-FLOW DATA - VI.B 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 42 0.80 536 
2 39 0.68 598 
3 31 0.82 680 
4 23 0.80 706 
5 13 0.70 720 
6 10 0.62 716 
7 13 0.65 716 
8 18 0.56 716 
9 31 0.56 710 
10 36 0.51 690 
11 0.40 636 
12 0.40 626 
13 0.46 644 
14 0.37 646 
15 0.40 630 
16 0.36 644 
17 0.43 622 
18 0.37 596 
19 0.43 578 
20 0.55 602 
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STOP-FLOW DATA - VI.B 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 140 2.98 
2 225 3.04 
3 250 2.55 
4 250 2.11 
5 280 1.23 
6 280 0.72 
7 250 0.68 
8 305 0.94 
9 250 1.80 
10 225 2.43 
11 225 2.92 
12 165 3.08 
13 165 3.16 
14 165 3.20 
15 165 3.21 
16 165 3.25 
17 165 3.37 
18 165 3.42 
19 165 3.49 
20 165 3.45 
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STOP-FLOW DATA - VI.C 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 2.16 2.16 
2 2.28 4.44 
3 2.08 6.52 
4 1. 97 8.49 
5 1. 85 10.34 
6 2.05 12.39 
7 2.19 14.58 
8 1. 93 16.51 
9 1.99 18.50 
10 2.25 20.75 
11 1. 99 22.74 
12 1. 92 24.66 
13 1. 91 26.57 
14 1. 74 28.31 
15 1.72 30.03 
16 1.99 32.02 
17 1. 97 33.99 
18 2.01 36.00 
19 1.95 37.95 
20 2.72 40.67 
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STOP-FLOW DATA - VI.C 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 43 0.57 520 
2 37 0.64 568 
3 24 0.68 632 
4 17 0.58 620 
5 12 0.56 628 
6 13 0.49 642 
7 22 0.49 616 
8 33 0.55 568 
9 42 0.37 546 
10 47 0.33 522 
11 0.34 508 
12 0.37 518 
13 0.32 508 
14 0.32 498 
15 0.33 476 
16 0.34 472 
17 0.39 452 
18 0.58 444 
19 0.48 436 
20 0.48 438 
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STOP-FLOW DATA - VII.A 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1. 46 1. 46 
2 1. 45 2.91 
3 1. 73 4.64 
4 1. 71 6.35 
5 1.96 8.31 
6 1. 47 9.78 
7 1.55 11. 33 
8 1.72 13.05 
9 1. 59 14.64 
10 1.63 16.27 
11 1.19 17.46 
12 1. 55 19.01 
13 1. 62 20.63 
14 1. 68 22.31 
15 1. 65 23.96 
16 1. 53 25.49 
17 1. 49 26.98 
18 1. 69 28.67 
19 1. 63 30.30 
20 3.10 33.40 
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PIG VII 
STOP-FLOW DATA - VII.A 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 50 4.04 266 
2 46 3.90 273 
3 37 4.37 336 
4 22 5.12 392 
5 12 4.53 343 
6 13 3.90 350 
7 20 3.38 336 
8 30 2.86 301 
9 46 2.21 294 
10 51 1.70 254 
11 1. 48 266 
12 1.27 266 
13 1.23 266 
14 1. 20 252 
15 1.30 238 
16 1.33 224 
17 1. 51 210 
18 1.68 189 
19 1.95 210 
20 2.38 182 
221 
PIG VII 
STOP-FLOW DATA - VII.A 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 N/D 3.19 
2 " 3.17 
3 " 3.19 
4 " 2.45 
5 " 1. 32 
6 " 0.78 
7 " 0.79 
8 " 1. 25 
9 " 2.20 
10 " 2.77 
11 " 3.08 
12 " 3.16 
13 " 3.20 
14 " 3.26 
15 " 3.32 
16 " 3.36 
17 " 3.41 
18 " 3.52 
19 " 3.61 
20 " 3.66 
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STOP-FLOW DATA - VII.B 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1. 09 1.09 
2 1. 45 2.54 
3 1. 60 4.14 
4 1. 74 5.88 
5 1.52 7.40 
6 1. 49 8.89 
7 1. 48 10.37 
8 1. 78 12.15 
9 1. 22 13.37 
10 1. 68 15.05 
11 1.62 16.67 
12 1.39 18.06 
13 1. 62 19.68 
14 1. 40 21.08 
15 1. 53 22.61 
16 1. 38 23.99 
17 1. 34 25.33 
18 1. 44 26.77 
19 1. 42 28.19 
20 2.57 30.76 
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STOP-FLOW DATA - VII.B 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 42 1. 03 324 
2 39 1. 00 327 
3 34 1.06 381 
4 20 1.12 417 
5 14 0.95 414 
6 12 0.85 402 
7 15 0.76 402 
8 24 0.70 378 
9 36 0.64 354 
10 46 0.52 330 
11 0.45 327 
12 0.39 318 
13 0.44 303 
14 0.42 309 
15 0.45 270 
16 0.50 234 
17 0.56 270 
18 0.56 276 
19 0.70 249 
20 0.88 240 
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STOP-FLOW DATA - VII.C 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1. 71 1. 71 
2 1.57 3.28 
3 1. 54 4.82 
4 1.16 5.98 
5 1.45 7.43 
6 1. 54 8.97 
7 1.36 10.33 
8 1. 58 11. 91 
9 1. 67 13.58 
10 1.78 15.36 
11 1. 53 16.89 
12 1. 43 18.32 
13 1. 24 19.56 
14 1.16 20.72 
15 1. 09 21. 81 
16 1. 43 23.24 
17 1.30 24.54 
18 1. 45 25.99 
19 1. 24 27.23 
20 2.31 29.54 
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STOP-FLOW DATA - VII.C 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 37 0.28 381 
2 33 0.40 408 
3 25 0.38 447 
4 17 0.36 468 
5 9 0.29 468 
6 10 0.25 441 
7 15 0.26 426 
8 25 0.20 417 
9 37 0.20 393 
10 44 0.16 357 
11 0.15 360 
12 0.12 339 
13 0.17 333 
14 0.13 315 
15 0.16 327 
16 0.21 294 
17 0.21 294 
18 0.23 279 
19 0.30 288 
20 0.35 282 
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STOP-FLOW DATA - VIII.A 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1. 88 1. 88 
2 1. 94 3.82 
3 1. 81 5.63 
4 1. 62 7.25 
5 1.66 8.91 
6 1. 74 10.65 
7 1. 59 12.24 
8 1. 60 13.84 
9 1.60 15.44 
10 1. 40 16.84 
11 1. 52 18.36 
12 1. 35 19.71 
13 1. 43 21.14 
14 1. 67 22.81 
15 1.31 24.12 
16 1. 36 25.48 
17 1. 26 26.74 
18 1. 30 28.04 
19 1. 47 29.51 
20 2.38 31. 89 
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STOP-FLOW DATA - VIII.A 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 35 0.47 1154 
2 20 0.42 1004 
3 11 0.26 964 
4 11 0.26 990 
5 12 0.30 944 
6 15 0.31 938 
7 27 0.27 900 
8 40 0.23 808 
9 55 0.25 686 
10 67 0.23 642 
11 0.22 630 
12 0.18 620 
13 0.37 518 
14 0.20 558 
15 0.29 480 
16 0.21 558 
17 0.25 510 
18 0.34 480 
19 0.29 548 
20 0.54 490 
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PIG VIII 
STOP-FLOW DATA - VIII.A 
SAMPLE ALUMINIUM CALCIUM 
(µg/L) (mg/dL) 
1 316 1. 71 
2 433 1.22 
3 399 0.65 
4 368 0.62 
5 333 0.55 
6 316 0.47 
7 268 0.74 
8 234 1. 76 
9 169 2.79 
10 152 3.51 
11 152 3.72 
12 152 3.72 
13 100 3.58 
14 134 3.60 
15 117 3.67 
16 117 3.69 
17 117 3.76 
18 117 3.83 
19 100 3.84 
20 82 3.75 
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STOP-FLOW DATA - VIII.B 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 2.10 2.10 
2 1. 78 3.88 
3 1. 78 5.66 
4 1.69 7.35 
5 1.51 8.86 
6 1. 45 10.31 
7 1. 63 11. 94 
8 1. 79 13.73 
9 1. 60 15.33 
10 1.83 17.16 
11 1. 85 19.01 
12 1. 82 20.83 
13 1. 78 22.61 
14 1. 34 23.95 
15 1. 43 25.38 
16 1. 53 26.91 
17 1. 62 28.53 
18 2.00 30.53 
19 1. .51 32.04 
20 1.70 33.74 
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STOP-FLOW DATA - VIII.B 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 40 0.19 940 
2 41 0.25 1124 
3 28 0.23 1110 
4 21 0.33 1074 
5 14 0.23 956 
6 14 0.20 1130 
7 20 0.21 1116 
8 30 0.19 886 
9 45 0.20 926 
10 54 0.17 886 
11 N/A 884 
12 0.16 934 
13 0.15 804 
14 0.21 824 
15 0.22 778 
16 0.09 754 
17 0.12 572 
18 0.25 564 
19 0.51 576 
20 0.34 526 
233 
PIG VIII 




































































STOP-FLOW DATA - VIII.C 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1. 75 1. 75 
2 1. 45 3.20 
3 1. 50 4.70 
4 1. 67 6.37 
5 1.55 7.92 
6 1. 40 9.32 
7 1. 48 10.80 
8 1. 52 12.32 
9 1. 61 13.93 
10 2.14 16.07 
11 1. 53 17.60 
12 1. 67 19.27 
13 1. 70 20.97 
14 1. 44 22.41 
15 1.59 24.00 
16 1. 64 25.64 
17 1. 32 26.96 
18 1. 45 28.41 
19 1. 76 30.17 
20 2.85 33.02 
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STOP-FLOW DATA - VIII.C 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 35 0.17 896 
2 26 0.26 1026 
3 20 0.26 1010 
4 12 0.20 1072 
5 9 0.11 928 
6 10 0.10 856 
7 16 0.10 844 
8 28 0.10 810 
9 39 0.11 654 
10 59 0.12 650 
11 0.11 616 
12 0.10 640 
13 0.11 590 
14 0.13 570 
15 0.11 568 
16 0.13 530 
17 0.13 534 
18 0.13 504 
19 0.06 464 
20 0.21 516 
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STOP-FLOW DATA - VIII.D 
SAMPLE URINE VOLUME CUMULATIVE URINE VOLUME 
( ml) ( ml) 
1 1.64 1. 64 
2 2.17 3.81 
3 2.11 5.92 
4 2.20 8.12 
5 2.07 10.19 
6 1. 95 12.14 
7 1.97 14.11 
8 2.04 16.15 
9 2.08 18.23 
10 2.50 20.73 
11 1. 70 22.43 
12 1.88 24.31 
13 1.99 26.30 
14 1. 96 28.26 
15 1. 69 29.95 
16 1. 83 31. 78 
17 1.75 33.53 
18 1.77 35.30 
19 1. 64 36.94 
20 2.52 39.46 
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STOP-FLOW DATA - VIII.D 
SAMPLE SODIUM PHOSPHATE CREATININE 
(mmol/L) (mg/dL) (µmol/L) 
1 33 0.14 798 
2 38 0.20 858 
3 28 0.20 712 
4 18 0.19 856 
5 12 0.15 796 
6 13 0.16 818 
7 24 0.19 766 
8 36 0.13 760 
9 53 0.10 610 
10 66 0.09 668 
11 0.09 586 
12 0.05 632 
13 0.09 566 
14 0.08 550 
15 0.13 538 
16 0.12 526 
17 0.16 474 
18 0.20 446 
19 0.19 472 
20 0.28 474 
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SAMPLE NO CREATININE INULIN CR/INULIN INULIN/CR FR.EXC.FIL. 
(µmol/L) (mg/dL) URINE RATIO PLASMA RATIO CR 
% 
1 1154 376 3.07 0.176 54.03 




SAMPLE NO CREATININE INULIN CR/INULIN INULIN/CR FR.EXC.FIL. 
(µmol/L) ( mg/dL) URINE RATIO PLASMA RATIO CR 
% 
1 940 211 4.45 0.169 75.39 
2 1124 247 4.55 " 77.01 3 1110 210 5.29 " 89.45 4 1074 211 5.09 " 86.14 5 956 202 4.73 " 80.09 6 1130 200 5.65 " 95.62 7 1116 187 5.97 " 101.00 8 886 199 4.45 " 75.35 9 926 167 5.54 " 93.84 10 886 168 5.27 " 89.25 11 884 159 5.56 II 94.09 
12 934 153 6.10 " 103.31 13 804 146 5.51 II 93.19 
14 824 141 5.84 II 98.90 
15 778 128 6.08 II 102.86 
16 754 128 5.89 II 99.69 




SAMPLE NO CREATININE INULIN CR/INULIN INULIN/CR FR.EXC.FIL. 
(µmol/L) (mg/dL) URINE RATIO PLASMA RATIO CR 
0 
'6 
1 896 181 4.95 0.129 63.98 




SAMPLE NO CREATININE INULIN CR/INULIN INULIN/CR FR.EXC.FIL. 
(µmol/L) (mg/dL) URINE RATIO PLASMA RATIO CR 
% 
1 798 161 4.96 0.143 70.91 
2 858 175 4.90 " 70.04 
3 712 165 4.32 " 61. 65 
4 856 152 5.63 " 80.45 
5 796 149 5.34 " 76.32 
6 818 148 5.53 " 78.96 
7 766 145 5.28 " 75.47 
8 760 136 5.59 " 79.83 
9 610 134 4.55 " 65.03 
10 668 113 5.91 " 84.45 
11 586 120 4.88 " 69.76 12 632 128 4.94 " 70.54 13 566 120 4.72 " 67.38 14 550 110 5.00 " 71. 43 15 538 99 5.43 " 77.63 16 526 102 5.16 " 73.67 17 474 100 4.74 " 67.71 18 446 91 4.90 " 70.02 19 472 90 5.24 " 74.92 20 474 92 5.15 " 73.60 
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IN MG/L 





CaCl2. . . 
D-Glucose. . 
Phenol red. 




L-Cysteine HCl . 
L-Cystine . . . 
L-Glutamine 
DL Glutamic acid 




DL-Leucine . . . 
L-Lysine HCl . 
DL-Methionine 
DL-Phenylalanine 
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ATP, disodium salt 
AMP . . . . . 
Ascorbic acid 
Biotin . . . 




i-Inos::..tol . . 
Menadione. . . . 
Nicotinic acid 




Riboflavin . . . 
Thiamine HCl . . 
DL-a-'I'ocopherol 
phosphate Na2 
Vitamin A . . 
Cholesterol . . . 
2-Deoxyribose 
D-Ribose . . . 
. . 10 
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